

## Electrophysiological Perspectives on Hybrid Ablation of Atrial Fibrillation

Faisal F. Syed, MBChB, Hakan Oral, MD

*Cardiac Arrhythmia Service, University of Michigan, Ann Arbor, MI.*

### Abstract

To overcome limitations of minimally invasive surgical ablation as a standalone procedure in eliminating atrial fibrillation (AF), hybrid approaches incorporating adjunctive endovascular catheter ablation have been proposed in recent years. The endovascular component targets residual conduction gaps and identifies additional electrophysiological targets with the goal of minimizing recurrent atrial arrhythmia. We performed a systematic review of published studies of hybrid AF ablation, analyzing 432 pooled patients (19% paroxysmal, 29% persistent, 52% long-standing persistent) treated using three different approaches: A. bilateral thoracoscopy with bipolar radiofrequency (RF) clamp-based approach; B. right thoracoscopic suction monopolar RF catheter-based approach; and C. subxiphoid posterior pericardioscopic ("convergent") approach. Freedom from recurrence off antiarrhythmic medications at 12 months was seen in 88.1% [133/151] for A, 73.4% [47/64] for B, and 59.3% [80/135] for C, with no significant difference between paroxysmal (76.9%) and persistent/long-standing persistent AF (73.4%). Death and major surgical complications were reported in 8.5% with A, 0% with B and 8.6% with C. A critical appraisal of hybrid ablation is presented, drawing from experiences and insights published over the years on catheter ablation of AF, with a discussion of the rationale underlying hybrid ablation, its strengths and limitations, where it may have a unique role in clinical management of patients with AF, which questions remain unanswered and areas for further investigation.

### Introduction

The traditional invasive cut-and-sew maze procedure, pioneered by Dr. Cox<sup>1,2</sup> and with subsequent revisions culminating in the Cox-maze III, has had a durably high success rate in treating atrial fibrillation (AF), with 80-90% of patients having maintained sinus rhythm without antiarrhythmic medications on long-term clinical follow-up.<sup>3,4</sup> Since the simplification of this procedure using surgical catheter ablation technologies as in the Cox-maze IV,<sup>5</sup> most maze procedures in the USA are facilitated with surgical catheter ablation.<sup>6</sup> Subsequently, minimally-invasive surgical approaches utilizing endoscopically delivered epicardial ablation were developed, parallel to developments in percutaneous catheter-based ablation strategies and technologies,<sup>7-14</sup> obviating the need for cardiopulmonary bypass and curtailing postoperative recovery, whilst maintaining a vantage for adjunctive interventions such as epicardial autonomic modulation and left atrial appendage (LAA) excision.<sup>15-21</sup> These

developments were accompanied by increasing number of patients having standalone surgery for AF, constituting 8% of all surgical AF ablations registered in the Society of Thoracic Surgeons Adult Cardiac Surgery Database between 2005 and 2010.<sup>22</sup> However, whereas published outcomes from ablation-facilitated open surgical Cox-maze IV and the traditional cut-and-sew Cox-maze III have been comparable,<sup>4, 23-26</sup> patients treated with minimally-invasive epicardial surgical ablation have fared less well, in particular those with non-paroxysmal AF.<sup>27, 28</sup> On pooled analysis of published results, 75% of paroxysmal, 67% of persistent and only 43% of long-standing persistent AF patients are free of arrhythmia recurrence off antiarrhythmic medications.<sup>27</sup> A recent systematic review estimated a 10-20% higher rate of recurrent atrial arrhythmias after minimally-invasive surgery as compared to open ablation-based surgery, and although there are no adequately controlled trials or registry data comparing the two approaches directly, this likely underestimates the difference as most open surgical AF ablations in published series have been in patients with long-standing persistent AF (56%, with 8% paroxysmal) whilst most minimally-invasive epicardial ablations were in those with paroxysmal AF (59%, with 8% long-standing persistent).<sup>28</sup>

Although the mechanisms underlying this observed difference in outcomes are not fully ascertained, electrophysiological observations during minimally invasive epicardial ablations or at the time of catheter ablation of recurrent atrial arrhythmias following such procedures<sup>29-33</sup> suggest that these paradoxically inferior results often

### Key Words:


Atrial Fibrillation, Hybrid Ablation, Surgical Ablation, Rotors, Maze.

### Disclosures:

None.

### Corresponding Author:

Dr. Hakan Oral,  
Cardiovascular Center, SPC 5853  
1500 E. Medical Center Drive  
Ann Arbor, MI 48109-5853



**Hybrid ablation: access, tools and lesions sets. Top and middle left: Left thoracoscopic access as part of bilateral clamp-based approach; lesion (large arrow) created by bipolar radiofrequency clamp (Atricure, West Chester, OH) at right pulmonary vein antrum (asterix). RL – right lung. From Pison, *J Am Coll Cardiol* 2012;60(1):54-61, with permission. Bottom left: Bipolar pen used for linear ablations in bilateral clamp-based approach. From Sakamoto, *J Thorac Cardiovasc Surg* 2008;136(5):1295-1301, with permission. Bottom middle: Lesion set in bilateral clamp-based approach, from Mahapatra, *Ann Thoracic Surg*, Volume 91, Issue 6, 1890 – 1898, with permission. Central: Suction monopolar radiofrequency catheter (Estech Cobra Adhere XL, Atricure, West Chester, OH) positioned over the posterior left atrium as used in the right-sided thoracoscopic approach. From Muneretto, *Innovations (Phila)* 2012;7(4):254-8, with permission. Top right: Transabdominal, transdiaphragmatic access used in convergent approach. From Gehi, *Heart Rhythm* 2013;10(1):22-8, with permission. Middle and bottom right: Vacuum irrigated unipolar radiofrequency device (Numeris Guided Coagulation System with VisiTrax, nContact Surgical, Inc, Morrisville, NC) used in convergent approach; epicardial (blue) and endocardial (red) lesion set in convergent approach. From Gersack, *J Thorac Cardiovasc Surg* 2014;147(4):1411-6, with permission.**

reflect the demonstrated limitations of current ablation tools in creating transmural lesions sets when applied endoscopically on the epicardium of the beating heart.<sup>34-36</sup> Up to 40% of patients undergoing minimally invasive AF surgery have been reported to develop recurrent atrial flutter, with 50% of isolated pulmonary veins having reconnected at time of repeat ablation,<sup>30</sup> which is significantly higher than rates of 5 to 10% reported following endocardial surgical ablation,<sup>37-39</sup> and is responsive to further catheter ablation.<sup>20</sup> By slowing conduction yet failing to impart conduction block, such lesions are not only ineffective at preventing fibrillatory wave propagation<sup>40</sup> and AF from recurring<sup>41-43</sup> but also establish the tissue substrate required for reentrant atrial tachycardia.<sup>44-54</sup> With multiple, incomplete lines, reentrant atrial tachycardia circuits become complex and increasingly challenging to subsequently map and ablate.<sup>29</sup>


To overcome these limitations of minimally invasive surgical ablation as a standalone procedure in abolishing AF, hybrid ablation was developed, incorporating an adjunctive percutaneous catheter procedure to bridge conduction gaps in the anatomically-based surgical ablation lines as well as additional targets determined electrophysiologically.<sup>55-59</sup> This paired utility of surgical and catheter based approaches has been advocated as providing the combined

advantage of both, whilst allowing each to overcome the limitation of the other.<sup>55,57,59</sup> Ensuring conduction block at the time of surgery significantly reduces recurrence rates; of 93 patients undergoing either open chest or minimally invasive surgical AF ablation, maintenance of AF off antiarrhythmic medications at 12 months was 87% with confirmation of conduction block vs 48% without.<sup>32</sup>


In this review, we critically appraise the published experience on hybrid ablation, placing it within the context of the experiences and insights attained over the years from catheter ablation of AF. In doing so, we provide a perspective on the rationale underlying hybrid ablation, its strengths and limitations, where it may have a unique role in clinical management of patients with AF, which questions remain unanswered and areas for further investigation.

### Systematic Review of Published Literature on Hybrid Ablation of Atrial Fibrillation

Peer-reviewed publications reporting on 5 or more clinical cases undergoing adjunctive minimally invasive epicardial ablation and percutaneous endovascular catheter ablation were identified using Pubmed.gov (US National Library of Medicine, National Institute of Health) using the search term “atrial fibrillation AND (hybrid OR convergent) AND (ablation OR surgery)” (last updated 3/4/2015). This was supplemented by searches on Google Scholar and review of individual studies’ references. We identified 11 unique studies reporting on a total of 432 patients who have undergone standalone hybrid ablation at 11 centers (7 European, 3 North American, 1 Asian) and pooled available demographic, procedural and outcome data of 432 (Tables 1 – 3).<sup>33,56,57,59-66</sup> We included 2 publications where we felt that duplication of case ascertainment was minimal on account of a limited data overlap in recruitment of a patient subset<sup>62,65</sup> and excluded 5 publications with probably significant patient overlap selecting in preference those publications which were more recent with greater patient numbers.<sup>55,67-70</sup> A further 4 studies (231



**Thoracic venous sources of atrial fibrillation triggers. Top: pulmonary vein and vena cavae. Arrows and asterix identify myocardium in venous structures adjoining the left and right atria. Bottom: Diagram depicting location of the ligament (or vein) of Marshall, the remnant of the left-sided superior vena cava, which has varying degrees of patency in adult life. From Desimone, *J Cardiovasc Electrophysiol* 2012;23(12):1304-9, with permission. LAA – left atrial appendage; LIPV/RIPV – left/right inferior/superior pulmonary vein; IVC/SVC – inferior/superior vena cava.**



**Figure 3:** Ablation lines created during left atrial ablation represented on a 3D electroanatomical mapping system (Carto™). Individual ablation lesions are represented by red tags. From Oral, *Circulation*. 2003;108(19):2355-2360, with permission.

patients) were not included as they were published in journals not indexed by the US National Library of Medicine.<sup>71-74</sup>

The 432 pooled patients had a mean age of 60 years (range, 56 to 63 years), mean CHADS2 scores (reported in 5 studies, n=250, 58%) 1 to 1.6, mean left atrial diameter (reported in all studies) 4.3 to 5.2 cm, mean left ventricular ejection fraction (reported in 11 studies, n=368, 85%) 47 to 62%, and mean AF duration (reported in all studies) 2.8 to 7.0 years (Table 1). AF was categorized in accordance with guidelines<sup>75</sup> as paroxysmal (individual episodes lasting  $\leq 7$  days) in 19% (83/432), persistent (continuous AF  $> 7$  days) in 29% (124/432) and long-standing persistent (continuous AF  $> 12$  months) in 52% (225/432). A history of prior AF ablation was present in 35% (112/319 with reported data). Four studies (n=163, 38%) included only persistent and/or long-standing persistent AF patients. No study reported inclusion of patients with valvular AF (i.e. associated with rheumatic mitral stenosis, prosthetic or bioprosthetic valve, or mitral valve repair<sup>75</sup>) or prior cardiac surgery, although these data were not specifically reported in 5 [n=245, 57%] and 4 [n=210, 49%] studies respectively, whilst 2 studies [n=123, 28%] included only lone AF patients.

The published experience encompasses 3 different surgical approaches, each utilizing unique radiofrequency ablation tools (Table 2, Figure 1): bilateral thoracoscopy with circumferential and linear lesions (sometimes referred to as LAMP [La Meir, Ailawadi, Mahapatra, Pison] hybrid ablation) created using bipolar radiofrequency clamps and ablation pens (Atricure, West Chester, OH) respectively (6 studies, n=194, 45%); right-sided thoracoscopy with simultaneous isolation of pulmonary veins and posterior left atrium using a suction monopolar radiofrequency catheter (Estech Cobra Adhere XL, Atricure, West Chester, OH) designed to deliver an encircling linear lesion (2 studies, n=64, 15%); and subxiphoid posterior pericardioscopy (through laparoscopic incision of the central diaphragmatic tendon) with linear ablation using a vacuum irrigated unipolar radiofrequency device (Numeris Guided Coagulation System with VisiTrax, nContact Surgical, Inc, Morrisville, NC, USA) to isolate or debulk the posterior left atrium and partially isolate the pulmonary veins (2 studies, n=174, 40%, referred to as the convergent procedure). Pulmonary vein isolation (PVI) was a common end-point in all studies. One clamp-based study<sup>33</sup> included 5 patients with severe COPD who underwent only right thoracoscopic radiofrequency epicardial ablation with adjunctive endovascular left-sided pulmonary vein cryoablation to avoid bilateral pneumothoraces.


In addition to the differences in epicardial lesions created by these

very different strategies and tools, timing of the endovascular catheter component also varied widely, from being performed immediately after surgery in 5 studies (“immediate-staged”, n=259, 60%) or after a delay ranging from 4 days to 3 months in 4 studies (“delayed-staged”, n=100, 23%), with 1 multicenter study (n=73, 17%) reporting an immediate-staged procedure in 2 centers, delayed at  $> 2$  weeks in 1 center, and 50:50 split between immediate and delayed at  $> 2$  months in 1 center (Table 2). The endovascular component itself varied significantly between studies, such as whether electroanatomical mapping was utilized, choice of linear ablation lesions and which patients these were performed in, whether physiological targets such as triggers and complex fractionated atrial electrograms (CFAE) were targeted, and selection of end-points including intraprocedural confirmation of conduction block and re-induction protocols. There was variation in ganglion identification and ablation, ligament of Marshall ablation, and LAA ligation or excision (Table 2). There was diversity in approaches to peri-procedural antiarrhythmic and anticoagulant management.

Such diversity in approach is not surprising given the relative infancy of minimally-invasive surgical AF ablation and the novel ablation tools used,<sup>27,76</sup> as well as lack of consensus within the ablation community itself on optimal strategies for persistent and long-standing persistent AF.<sup>77</sup> An appreciation of electrophysiological principles underlying AF mechanisms and ablation approaches is central to understanding the role of these various approaches as therapeutic strategies for AF and their relative shortcomings.

### Electrophysiological Perspective 1 – Heterogeneity of Atrial Fibrillation Mechanisms and Implications for Tailored Therapy

The pathogenesis of AF is often multifactorial. Applying the same therapy as a panacea may risk overtreating some and not addressing underlying mechanisms in others. Whilst the success of the maze procedure is consistent with the principle that a critical mass of atrial tissue is required to sustain fibrillatory conduction,<sup>116-118</sup> the cumulative experience from catheter ablation suggests both initiating triggers and arrhythmogenic substrate need to be addressed,<sup>119, 120</sup> particularly in patients with persistent AF,<sup>48, 79, 80, 82-89, 91, 92, 94, 121-129</sup> and underlying risk factors are identified and treated.<sup>104, 105</sup>



**Figure 4:** Human heart demonstrating cross-section of the mitral isthmus. The thickness of the atrial myocardium, epicardial fat and associated vasculature are demonstrated. From Becker, *J Cardiovasc Electrophysiol* 2004;15(7):809-812, with permission. LCx – left circumflex artery; GCV – great cardiac vein; LIPV – left inferior pulmonary vein.

**Table 1: Systematic Review of Hybrid Ablation Studies – Patient Demographics**

First Author	No. patients\$	Publication Year	Institution(s)	Procedural Approach	Energy source	Age (mean±SD, years)	PAF	PrAF	LSPrAF	Lone AF only
Mahapatra <sup>57</sup>	15	2011	University of Virginia, Charlottesville, USA	Thoracoscopic Clamp-based	RF	59.5±2.4	0	9	6	No
Lee <sup>56</sup>	7	2011	Northwestern Memorial Hospital, Northwestern University, Chicago, USA	Thoracoscopic Clamp-based	RF	NA	NA	NA	NA	No
La Meir <sup>59</sup>	19	2012	University Hospital Maastricht, Maastricht, The Netherlands	Thoracoscopic Encircling Catheter	RF	60.8±8.6	5	4	10	No
Pison <sup>33</sup>	26	2012	University Hospital Maastricht, Maastricht, The Netherlands	Thoracoscopic Clamp-based	RF±cryoballoon*	57.2±8.6	15	10	1	No
Bisleri <sup>60</sup>	45	2013	University of Brescia Medical School, Brescia, Italy	Thoracoscopic Encircling Catheter	RF	62.3±9.8	0	0	45	Yes
Gehj <sup>61</sup>	101	2013	FirstHealth Arrhythmia Center, Pinehurst and University of North Carolina at Chapel Hill, Chapel Hill, USA	Subxiphoid Pericardioscopic (Convergent)	RF	62.9±9.6	17	37	47	No
La Meir <sup>62</sup>	35	2013	University Hospital Maastricht, Maastricht, The Netherlands	Thoracoscopic Clamp-based	RF	57.1±9.5	16	8	11	No
Kurfirsh <sup>63</sup>	30	2014	Hospital Ceske Budejovic, Ceske Budejovice, Czech Republic	Thoracoscopic Clamp-based	RF	61±8	0	0	30	No
Lee <sup>64</sup>	10	2014	Samsung Medical Center, Seoul, South Korea	Thoracoscopic Clamp-based	RF	56.1±7.6	1	0	9	No
Pison <sup>65</sup>	78	2014	University Hospital Maastricht, Maastricht, The Netherlands	Thoracoscopic Clamp-based	RF	60.5±7.5	29	34	15	Yes
Gersak <sup>66</sup>	73	2014	Multicenter¥ (Slovenia, Poland, Germany, France)	Subxiphoid Pericardioscopic (Convergent)	RF	56.3±10.5	0	22	51	No
<b>TOTAL**</b>	<b>432</b>					<b>mean 60.0</b>	<b>83</b>	<b>124</b>	<b>225</b>	

\*\*Excludes 7 patients reported by Lee et al<sup>56</sup> as results pooled with 18 patients undergoing non-hybrid minimally invasive AF surgery; \$Additional 8 paroxysmal AF patients not included on account of excluding one study (8 paroxysmal AF and 28 long standing persistent AF)<sup>79</sup> with significant overlap in reported patients with Bisleri et al.<sup>60</sup>; ¥University of Ljubljana Medical Center, Ljubljana, Slovenia; Silesian Center For Heart Diseases, Zabrze, Poland; Herz-und Gefaesszentrum, Bad Bevensen, Germany; L'Institut Mutualiste Montsouris, Paris, France  
PAF – Paroxysmal AF, PrAF – persistent AF, LSPrAF – long-standing persistent AF; NA – not available; LVEF – left ventricular ejection fraction; RF – radiofrequency

## Electrophysiological Perspective 2 – Insights from Catheter Ablation of Paroxysmal and Persistent Atrial Fibrillation

A major breakthrough in catheter ablation of AF was the finding that myocardial extensions into the pulmonary veins, previously recognized anatomically<sup>132</sup> and present in almost all human hearts (Figure 2),<sup>133</sup> are a dominant and progressive source of AF triggers amenable to ablation.<sup>134,135</sup> The mechanistic cogency of this approach was supported by studies demonstrating that isolating arrhythmogenic veins acutely terminates AF and prevents AF reinduction<sup>140</sup> even when tachycardia persists within the vein,<sup>140,144-146</sup> and also reduces arrhythmia recurrence compared to focal ablation<sup>147</sup> likely by addressing recurrent triggers from elsewhere in the pulmonary veins<sup>148</sup> or inter-connected veins.<sup>149,150</sup> Once it was realized that atrial myocardium adjacent to the pulmonary ostia, i.e. in the pulmonary vein antra, is a critical source of triggers leading to recurrence after ostial PVI,<sup>151</sup> in keeping with its histological and electrical homogeneity with the venous myocardial sleeves,<sup>152</sup> the approach was further modified to incorporate these areas (antral PVI or wide-area circumferential ablation [WACA]) with a further reduction in arrhythmia recurrence than with ostial PVI.<sup>153-157</sup> In addition to isolating venous<sup>146,158-160</sup> and antral arrhythmogenic foci,<sup>151,161-164</sup> proposed mechanisms have included disrupting pulmonary ostial anchors for AF drivers (discussed below)<sup>128,165,166</sup> and interrupting neuronal connections.<sup>81,167,168</sup> A number of randomized clinical trials have demonstrated the efficacy of this approach as a therapeutic strategy for paroxysmal AF,<sup>7,9,10,169-174</sup> and of consecutive patients undergoing radiofrequency PVI, approximately 75% and 90% are rendered arrhythmia-free off antiarrhythmic therapy after 1 and 2 ablation procedures, respectively,<sup>99</sup> and at 10 years, 75% of patients

are arrhythmia free, although 40% require repeat ablation and there have been evolving approaches and technologies over this time.<sup>100,175</sup> In addition to symptomatic benefit and quality of life improvement, there is a significantly lower rate of progression to persistent AF (0.5-0.6% per year)<sup>100,176,177</sup> compared with pharmacological therapy (8.6% per year).<sup>178</sup>

The catheter ablation experience allowed for additional insights into the pathophysiological significance of non-pulmonary thoracic venous myocardium. Atrial myocardium extending into the superior vena cava, seen in 80% of human hearts (Figure 2),<sup>133</sup> has similar electrophysiological characteristics to pulmonary venous extensions and can be a source of AF triggers.<sup>179,180</sup> It is also present in the coronary sinus, ligament of Marshall and, least commonly, azygous vein (6%).<sup>133</sup> Myocardium within the coronary sinus may be a source of rapid repetitive electrical activity during AF and electrically disconnecting it from the left atrium reduces sustained AF induction, suggesting a role in perpetuating AF.<sup>181</sup> The ligament of Marshall (Figure 2) is an epicardial remnant of the left superior vena cava, which maintains 3-French probe patency in 70% of hearts and consistently overlies the endocardial left lateral ridge between the pulmonary veins and left atrial appendage.<sup>133</sup> It contains both autonomic nerves and muscle fibres, the density of which varies along its length,<sup>182</sup> implicated in triggering or sustaining AF<sup>183</sup> and providing electrical continuity between the coronary sinus and pulmonary veins.<sup>184</sup>

Through experience with ablation, there has also been improved understanding on mechanisms and management of post-ablation atrial arrhythmia. Although early arrhythmia recurrence (<3 months) is a powerful predictor for long-term recurrence,<sup>185-190</sup> a significant proportion (30%) may go on to be arrhythmia free in the long-term

without repeat ablation,<sup>185,187</sup> and early restoration of sinus rhythm during this period reduces long-term recurrence rates,<sup>191</sup> although additional antiarrhythmic use does not add incremental value to cardioversion.<sup>192-195</sup> For late recurrence (>3 months), repeat ablation is superior, as demonstrated by one randomized trial of paroxysmal AF patients with recurrence after antral PVI, with reduced AF burden, symptoms and progression to persistent AF (4 vs 23% at 36 months) compared to antiarrhythmic therapy.<sup>196</sup> This is mechanistically consistent with studies demonstrating that recurrence after PVI for paroxysmal AF is usually related to reconnected pulmonary vein conduction,<sup>43,47,146,158,177,197-201</sup> likely due to reversible ablation injury with absent circumferential scar on MRI,<sup>202-205</sup> or the presence of extrapulmonary ectopic AF triggers.<sup>151,158,162</sup> Extrapulmonary triggers are noted spontaneously in about 10% of patients undergoing AF ablation, being several fold more frequent with increasing AF burden and duration (3% of paroxysmal, 8% of persistent and 19% of long-standing persistent patients),<sup>99</sup> and in up to 45% following induction with pacing or isoproterenol infusion, most commonly arising from the posterior left atrial wall (20-40%), left atrial appendage (30%), or superior vena cava (30-40%), with a minority from the left atrial roof (8%), ligament of Marshall (8%), crista terminalis (5-10%), coronary sinus (1-10%), and interatrial septum (1-5%).<sup>151,163,206-210</sup> It is unknown whether routinely targeting these regions improves outcomes when they are not evident sources of triggers during ablation. For instance, routinely isolating the SVC as a dominant site of extrapulmonary venous triggers has been advocated,<sup>180</sup> whilst randomized trials testing this approach have reported conflicting results.<sup>211-213</sup>

To summarize, in keeping with the predominant trigger-based mechanism underlying paroxysmal AF, catheter ablation studies have demonstrated that an anatomically guided approach to PVI leads to sustained improvement off antiarrhythmic drugs in the majority of patients and offers a definite end point of electrical isolation of the pulmonary vein. Although the extent of atrial fibrosis correlates weakly with clinical phenotype,<sup>78</sup> with some paroxysmal AF patients having high atrial fibrosis burden, systematic substrate modification offers no incremental benefit,<sup>214-222</sup> even with late recurrent paroxysmal AF requiring re-ablation,<sup>223</sup> and may even predispose to macroreentrant atrial tachycardias.<sup>216,224</sup>

This contrasts with insights gained from catheter ablation of persistent and long-standing persistent AF, where dominant fibrillating frequency shifts away from the pulmonary veins to other left or even right atrial sites<sup>144,161</sup> with PVI offering limited success on its own<sup>225-228</sup> and additional substrate modification becoming necessary to improve ablation outcomes,<sup>8,131,157,229,230</sup> all in keeping with the underlying transition from a predominant trigger-based paradigm to one with increasing influence from extrapulmonary drivers and atrial substrate.<sup>128,209,231</sup> However, there is mechanistic overlap, such that in persistent AF there is evidence of ongoing dynamic interplay between pulmonary vein triggering and atrial activation<sup>144</sup> and PVI may acutely reduce left atrial dominant activation frequency,<sup>232</sup> partially organize AF without necessarily affecting dominant frequency,<sup>233</sup> or acutely terminate AF.<sup>121,144,227</sup> Accordingly, atrial substrate modification alone without PVI results in inferior outcomes.<sup>228,234,235</sup> Nonetheless, atrial substrate, no matter how defined, is a strong predictor of recurrence after catheter ablation of persistent AF<sup>78,201,236-238</sup> and outcomes have been better with more extensive atrial substrate modification.<sup>124,230</sup> To what extent this

reflects current uncertainty over how best to identify pathogenic versus bystander substrate and appropriate end-points for ablation are areas of ongoing investigation.<sup>131</sup>

### Electrophysiological Perspective 3 – Successful Substrate Modification and Ablation End Points in Persistent Atrial Fibrillation

An intriguing finding from the PRAGUE-12 randomized trial is that restoration of sinus rhythm was significantly higher with increasingly persistent AF comparing maze to no maze in patients undergoing cardiac surgery (paroxysmal 62 vs. 58%, persistent 72 vs. 50% and long-standing persistent AF 53 vs. 14%,  $P < 0.001$ ).<sup>239</sup> The ability to observe in real time the effects of progressive substrate modification on atrial activation locally, remotely and globally whilst correlating this with structural, functional, and outcome data have allowed for novel insights into mechanism underlying arrhythmia and ablation efficacy in persistent and long-standing persistent AF. Improved catheter ablation outcomes have been reported when additional substrate modification is incorporated in an individualized, stepwise fashion to either reduce AF dominant frequency (>11%)<sup>240</sup> or terminate AF,<sup>129,238</sup> with adjunctive ablation of spontaneous and inducible atrial tachycardias.<sup>127,241,242</sup> With this approach, long-term freedom from AF off antiarrhythmic medication has been reported in 65-75% of patients,<sup>129,238,240,242</sup> and though 15-30% of patients with long-standing AF may require 3 or more procedures, recurrences are more likely to be from reentrant atrial tachycardia rather than recurrent AF,<sup>129,238</sup> albeit the benefits of AF termination decline with longer AF duration (>3 years in one study).<sup>243</sup> There is currently no consensus on what constitutes optimal substrate modification in persistent AF, with reported benefit from an anatomical approach through creating point-by-point ablation lines (linear ablation) following the success of the surgical maze procedure,<sup>46,51,229,232,244-246</sup> isolating the posterior left atrium in this manner,<sup>247,248</sup> ablating sites with complex fractionated atrial electrograms (CFAE) during fibrillatory conduction as a strategy to modify electrical substrate;<sup>217,219,226,234,249-251</sup> identifying and ablating focal drivers,<sup>109,113,123,126,128,252,253</sup> and ablating autonomic ganglia as AF modulators.<sup>82,84,86,88,91,92,254</sup>

The most extensively investigated linear ablation lesions during catheter ablation are the roof line, which connects the superior pulmonary veins (to mitigate risk of atrio-esophageal fistula from ablating over the esophagus posteriorly), and mitral isthmus line connecting the left inferior pulmonary venous antrum to the mitral annulus (Figure 3).<sup>48,153,232</sup> When such ablation is successful, it results in dominant activation frequency reduction and cycle length prolongation, which may progress with further ablation to AF termination, often to a macroreentrant atrial tachycardia circuiting around the left atrial roof, mitral isthmus, or cavotricuspid isthmus.<sup>48,232</sup> Of those still in AF on completion of antral PVI, 60% are left non-inducible for AF after one linear lesion and 95% after two.<sup>121</sup> Analyzing frequency-domain transformed activation signaling during linear ablation reveals that acute reductions in dominant activation frequency do not occur until completion of conduction block and coincide with disappearance of discreet lower frequency sources, characteristics of which were consistent with reentrant drivers, an effect not seen after PVI or CFAE ablation in this study.<sup>232</sup> Linear ablation may therefore work by disrupting localized reentrant drivers. Results from whole atrial phase and organization index mapping also suggest this.<sup>128,166,255</sup> In addition, linear ablation may reduce subsequent

**Table 2: Systematic Review of Hybrid Ablation Studies – Ablation Details**

First Author	No. patients	Ablation Technology	Epicardial Atrial Ablation	Intraprocedural Confirmation of Conduction Block: Epicardial	Ganglion Ablation (identification method)	LOM ablation	LAA Intervention	Endocardial Ablation: Staging	Endocardial Ablation	Electroanatomical Mapping	Confirming Conduction Block	Findings	Intervention	Reinduction	Triggers	Flutters
Thoracoscopic Clamp-based Approach (n=194, 45%)* **																
Mahapatra <sup>57</sup>	15	Bipolar clamp, bipolar linear RF pen (Atricure, West Chester, OH)	Bilateral PVI, roof line, anterior line, mitral isthmus line, CS ablation, SVC isolation	PVI: entrance ± exit: linear: none	Yes (HFS)	Yes	Excision (staple)	Delayed staged 4.3±1.3 days	Yes	Yes	PV bidirectional block, SVC isolation, bidirectional block across linear lesions, AF inducibility (isoproterenol)	Gaps in 0 PVI and SVC lesions, 27% (4/15) of roof lines and 27% (4/15) of mitral isthmus lines	Consolidation of surgical ablation lines, CTI line, CS ablation, mitral isthmus line and CFAE ablation if AF inducible, ablation of inducible flutters ablated	isoproterenol	No	Yes
Lee <sup>56</sup>	7	Bipolar RF clamp, monopolar RF pen (Medtronic, Minneapolis, MN)	Bilateral PVI	PVI: entrance ± exit: linear: bidirectional	Yes (HFS)	No	Excision (staple)	Delayed staged >3 months if recurrent AF/flutter	No	Yes (presumed)	PV bidirectional block, criteria for block across lines not stated	PV reconnections in all 7 patients (mean 2 per patient) at 6±3 months, all with confirmed entrance and/or exit block at time of surgery	Consolidation of surgical ablation lines, roof and mitral isthmus line, CTI line if typical flutter	Unknown	Yes	Yes
Pison <sup>33</sup>	26	Bipolar clamp, bipolar linear RF pen (Atricure, West Chester, OH)	Bilateral PVI, box lesions, roof line, mitral isthmus line, CS ablation, intercaval line, SVC isolation. Stepwise based on electrophysiological endpoint of non-inducibility of atrial arrhythmia.	PVI: entrance + exit: linear: bidirectional	No	No	Excision (staple)§	Immediate staged	No	No	PV bidirectional block, bidirectional block across linear lesions	Gaps in 0 PVI lesions, 23% (5/22) of box and 100% (3/3) of mitral isthmus lines	Consolidation of surgical ablation lines, CTI line if typical flutter (n=3)	Rapid atrial pacing and isoproterenol	No	Yes
La Meir <sup>62</sup>	35	Bipolar clamp, bipolar linear RF pen (Atricure, West Chester, OH)	Bilateral PVI, box lesion, mitral isthmus line*, CS ablation, intercaval line*, SVC isolation*	PVI: entrance + exit: linear: bidirectional	Yes (HFS)	No	Exclusion (staple or clip)§	Immediate staged	No	No	PV bidirectional block, bidirectional block across linear lesions, AF inducibility (rapid atrial pacing)	Gaps in linear ablation lesions in 14% (5/35)	Consolidation of surgical ablation lines, additional linear ablation if AF inducible, CTI line if typical flutter (n=3)	Rapid atrial pacing and isoproterenol	No	No
Kurfirst <sup>63</sup>	30	Bipolar clamp, bipolar linear RF pen (Atricure, West Chester, OH)	Bilateral PVI, box lesion, additional roof line	PVI: entrance + exit: linear: bidirectional	Yes (HFS)	Yes (ligation + ablation)	Exclusion (clips)§	Delayed staged 3 months	Yes	Yes	PV entrance block, unidirectional block across linear lesions, AF inducibility (rapid atrial pacing)	Gaps in PVI lesions in 87% of right PV, 77% of left PV, 67% of roof lines, and 40% of inferior lines	Consolidation of surgical ablation lines, CTI line and mitral isthmus line, ablation of line, ablation of inducible flutters	Rapid atrial pacing	No	Yes
Lee <sup>64</sup>	10	Bipolar clamp, bipolar linear RF pen (Atricure, West Chester, OH)	Bilateral PVI, inferior line	No	Yes (HFS)	Yes	Excision (staple)	Delayed staged 4 days in 8/10	Yes	Yes	PV isolation (not detailed)	Gaps in PVI lesions in 12.5% (1/8)	Consolidation of surgical ablation lines, CTI line in 6/8	No	No	No

First Author	No. patients	Ablation Technology	Epicardial Atrial Ablation	Intraprocedural Confirmation of Conduction Block: Epicardial	Ganglion Ablation (identification method)	LOM ablation	LAA Intervention	Endocardial Ablation: Staging	Endocardial Ablation	Electroanatomical Mapping	Confirming Conduction Block	Findings	Intervention	Reinduction	Triggers	Flutter
Pison <sup>65</sup>	78	Bipolar clamp, bipolar linear RF pen (Atricure, West Chester, OH)	Bilateral PVI, box lesion, mitral isthmus line§, CS ablation, intercaval line§, SVC isolations§	PVI: entrance + exit; linear: bidirectional	Yes (unknown)§	No	Exclusion (staple or clip)§	Immediate staged	No¶	No¶	PV bidirectional block, bidirectional block across linear lesions, AF inducibility (rapid atrial pacing)	Gaps in 0 PVI lesions and 36% (28/78) of box lesions	Consolidation of surgical ablation lines, CTI line if typical flutter (n=11), mitral isthmus line completion if perimitral flutter (n=10)	Rapid atrial pacing and isoproterenol	No	No
Thorascopic Encircling Catheter-based Approach (n=64, 15%)* **																
La Meir <sup>69</sup>	19	Encircling suction monopolar RF catheter (Estech Cobra Adhere XL, Atricure, West Chester, OH)	Encircling lesion set - bilateral PVI and box lesion	No	(as part of box lesion)#	No	No	Immediate staged	No¶	No¶	Entrance and/or exit block across linear lesions	Gaps in 89% (17/19) of PVI lesions and 100% (19/19) box lesions	Consolidation of surgical ablation lines, mitral isthmus line in persistent AF patients (n=3), CTI line if typical flutter seen (n=3)	No	No	No
Bisler <sup>60</sup>	45	Encircling suction monopolar RF catheter (Estech Cobra Adhere XL, Atricure, West Chester, OH)	Encircling lesion set - bilateral PVI and box lesion	PVI: entrance ± exit; linear: unidirectional	No	No	No	Delayed staged 30-45 days	Yes	Yes	PV bidirectional block, bidirectional block across linear lesions, AF inducibility (rapid atrial pacing)	PV reconnections (7%, 3/45) representing 3/4 with only exit block and 0/41 with bidirectional block immediately after surgical ablation	Consolidation of surgical ablation lines, CFAE if AF inducible (n=20), CTI line if typical flutter (n=11)	Rapid atrial pacing	No	Yes
Subphoid Convergent Approach (n=174, 40%)* **																
Gehl <sup>61</sup>	101	Vacuum irrigated unipolar RF device (Numeris Guided Coagulation System with VisiTrax, nContact Surgical, Inc, Morrisville, NC, USA)	Non-encircling bilateral atrial lesions, box lesion, additional roof line, mitral isthmus line*, CS ablation	PVI: none; linear: unidirectional	No	Yes (undissected)	No	Immediate staged	Yes	Yes	PV bidirectional block, unidirectional block across linear lesions, AF inducibility (rapid atrial pacing)	Gaps in PVI lesions in 4% (4/101)	Consolidation of surgical ablation lines, additional roof line (n=90), CS ablation (n=73), mitral isthmus line (n=84), CTI line (n=99), CFAE ablation (n=29). Stepwise based on electrophysiological endpoints of termination to sinus rhythm with no re-inducibility of AF or termination to atrial flutter/tachycardia	Rapid atrial pacing	No	No

First Author	No. patients	Ablation Technology	Epicardial Atrial Ablation	Intra-procedural Confirmation of Conduction Block: Epicardial	Ganglion Ablation (identification method)	LOM ablation	LAA Intervention	Endocardial Ablation: Staging	Endocardial Ablation	Electroanatomical Mapping	Confirming Conduction Block	Findings	Intervention	Reinduction	Triggers	Flutters
Gersak <sup>66</sup>	73	Vacuum irrigated unipolar RF device (Numeris Guided Coagulation System with VisiTrax, nContact Surgical, Inc, Morrisville, NC, USA)	Non-encircling bilateral atrial lesions, box lesion	No	No	Yes (undissected)	No	Mixed□	Mixed	Mixed	Entrance and/or exit block across linear lesions and PV	Gaps in all PVI at sites of pericardial reflections - superior margins bilaterally and inferior margin of right inferior pulmonary vein antrum.	Consolidation of surgical ablation lines	No	No	No

\*\*Excludes 7 patients reported by Lee et al<sup>156</sup> as results pooled with 18 patients undergoing non-hybrid minimally invasive AF surgery; §Selected patients only; \*Persistent and/or long-standing persistent AF patients only; #Dissection of ganglion fat pads prior to box lesion application and HFS confirmation of all except right inferior ganglion; □Immediate staged in 2 centers, delayed at >2 weeks in 1 center, 50% immediate and 50% delayed >2 months in 1 center; |Electroanatomical mapping was not utilized in Slovenia; †Sites of epicardial ablation identified with fluoroscopic visualization or ablation device in situ. N/A - not applicable - performed as part of box lesion; CS - coronary sinus; CFAE: complex fractionated atrial electrograms

macro-reentrant atrial tachycardia by creating lines of conduction block across critical anatomical isthmi, yet predispose to it when conduction block is not achieved.<sup>51, 54</sup> The major limitation of linear ablation is therefore difficulty in achieving sustained conduction block,<sup>50</sup> particularly at the mitral isthmus (Figure 4) where 40-70% of patients require additional epicardial ablation from within the coronary sinus and 10-35% are left without conduction block,<sup>256-258</sup> especially in areas with anatomical irregularity (such as with a pouch), or interpositioned coronary vessels presumably causing a heat sink.<sup>257-259</sup> Even if successful conduction block is achieved at index procedure, late recovery of mitral isthmus conduction is seen in 75% of instances (much higher than after cavotricuspid isthmus block [25%]) and predisposes to perimitral flutter.<sup>260</sup> The incidence of perimitral flutter is higher after routine mitral isthmus ablation and requires further reablation to achieve lasting freedom from recurrence.<sup>53</sup>

As with antral PVI, gaps in conduction block in linear lesions resulting in reentrant atrial tachycardias is the most common cause for arrhythmia recurrence,<sup>45, 46, 50-52, 245</sup> and may explain why the recently published STAR AF II randomized trial,<sup>261</sup> in which linear ablation resulted in acute conduction block in only 74% of patients and intraprocedural AF termination in 22%, failed to demonstrate benefit of linear ablation over antral PVI, and also why a recent meta-analysis demonstrated a significant reduction of AF recurrence with linear ablation but not with more extensive linear lesion sets.<sup>235</sup> In addition, although patients may manifest with perimitral flutter following persistent AF ablation, they still stand to benefit from confirmation of PVI and ablation of extra-pulmonary triggers, which may by itself result in more patients having reduced arrhythmia recurrence than if the mitral isthmus alone is ablated and blocked, indicating that triggering may underlie some macroentry post-ablation flutters.<sup>252</sup> As for routinely creating linear lesions in the right atrium, cavotricuspid isthmus ablation during AF ablation does not reduce long-term arrhythmia recurrence<sup>262, 263</sup> unless typical atrial flutter is demonstrated either clinically or during the ablation procedure.<sup>264, 265</sup> These principles also extend to effective surgical lesion sets.<sup>29</sup>

Limiting lesion sets also reduces the likelihood of complications, as illustrated by a recent meta-analysis comparing left atrial and biatrial maze which reported equivalent long-term success but with increased pacemaker implantation with biatrial maze.<sup>266</sup>

In a prior study CFAE ablation was reported to significantly improve ablation outcomes as an adjunct to PVI, but as standalone therapy the results were inferior to PVI (1 year arrhythmia-free rates 74 vs. 48 vs. 29% after one procedure in the STAR AF trial).<sup>234</sup> In about 20% of patients, AF terminates whilst ablating a CFAE,<sup>267, 268</sup> and an acute decrease in dominant frequency with CFAE ablation predicts reduced recurrence of AF.<sup>269</sup> Certain CFAEs are more likely to terminate AF or reduce its dominant activation frequency than others, such as those with greater duration of continuous activity or complexity,<sup>270-273</sup> whilst other CFAEs may represent bystander activation as suggested by studies demonstrating a reduction in CFAE number and location immediately following PVI or linear ablation.<sup>268, 271, 274</sup> Judicious selection of target sites is therefore needed, whilst identifying appropriate CFAE targets based on grading complexity is somewhat subjective and can be erroneously overestimated at overlapping structures including the interatrial septum. This may explain why, when guided by automated software protocols, CFAE ablation was reported to offer no additional benefit to antral PVI by the STAR AF II trial<sup>261</sup> and, as reported by another randomized trial, have inferior outcome to linear ablation despite more extensive lesions with greater cardiac enzyme release.<sup>275</sup> Further evidence of the importance of strategic CFAE ablation comes from a trial demonstrating no added benefit when right atrial CFAE ablation is routinely added to left atrial CFAE ablation.<sup>114</sup> The three published randomized studies directly comparing linear with CFAE ablation have reported either inferior performance of CFAE ablation,<sup>275</sup> as noted above, or equivalence of the two procedures,<sup>261, 276</sup> though with CFAE ablation resulting in higher rates of intra-procedural AF termination<sup>261</sup> and recurrences which are less likely fibrillation and more likely atrial tachycardia.<sup>276</sup>

The observation that terminating or slowing AF by ablation at discreet

sites modifies atrial substrate in a manner which renders the atrium significantly less likely to fibrillate suggests that the influence of even advanced substrate surrogates in determining recurrence can be overcome by focal ablation.<sup>128, 166, 245, 255, 267-273</sup> Whole atrial activation, phase, frequency and organizational index mapping has identified the presence of rotor-like activity and focal high-frequency sources driving AF.<sup>111-113, 123, 126, 128, 166, 277-283</sup> Ablation of these domains acutely terminates AF,<sup>128, 255</sup> though with longer durations of AF these drivers become more numerous and acute termination is less frequent (75% and 15% of persistent and long-lasting AF terminated, respectively, >6 months cutoff).<sup>128</sup> Though their location varies between individuals,<sup>123, 128, 255, 282</sup> they are predominantly left atrial (70%), with the rest being right atrial (30%),<sup>128, 255</sup> and demonstrate relative spatiotemporal stability with most meandering over 5-10 cm<sup>2</sup> areas around the pulmonary antra, antrally-associated septum and appendage, or left inferior wall/coronary sinus,<sup>128</sup> consistent with earlier data identifying these as sites where ablation is most likely to terminate AF.<sup>245</sup> What determines the observed relationship to these critical areas is unknown<sup>284</sup> and likely involves interplay between individual variation in atrial and pulmonary ostial geometry,<sup>285</sup> fiber orientation and anisotropy,<sup>286-288</sup> fibrosis,<sup>289-291</sup> regional variation in autonomic innervation and tissue response to autonomic input,<sup>83, 85, 86, 292</sup> and geometrically governed variability in exposure to mechanical stress and pressure.<sup>293-295</sup> By imaging fibrosis using MRI, the likelihood of recurrent arrhythmia after ablation has been correlated to the extent of fibrosis left unablated, indicating that substrate modification works best when it targets such fibrotic areas, likely by converting proarrhythmic tissue with heterogeneous fibrosis to homogenous inert scar.<sup>230</sup> A stepwise ablation approach also effectively reduces intrinsic scar burden,<sup>296</sup> indicating that both electrophysiologically and anatomically defined targets are likely colocalized. An approach tailored to targeting low voltage (<0.5mV) sites during sinus rhythm as areas representing fibrosis was recently shown to be feasible and associated with comparable outcomes to patients without any atrial scar.<sup>297</sup>

These data provide a mechanistic link between substrate, clinical characterization of AF and the observed responses to ablation. By identifying individual-specific mechanistic targets, providing novel insights into the role of atrial structural changes,<sup>286-288, 291, 297, 298</sup> better understanding why the currently established substrate modification strategies of linear and CFAE ablation sometimes demonstrate greater effect<sup>128, 232, 271, 280, 299, 300</sup> than at other times,<sup>261, 274, 298, 301-303</sup> these approaches raise the possibility that successful persistent AF ablation need not necessarily depend on standardized, extensive atrial compartmentalization or debulking by providing novel patient-specific ablation end-points,<sup>126, 128, 230, 281, 297, 304</sup> though this remains an area of ongoing investigation.

#### Electrophysiological Perspective 4 – Creating Effective Ablation Lesions: Endocardial vs. Epicardial Approaches

As with the endocardial approach, demonstrating effective conduction block across linear lesions is key to successful epicardial AF ablation.<sup>29, 32</sup> With viable myocardial strands as thin as 1 mm allowing for electrical propagation,<sup>40</sup> creating contiguous transmural lesions is the goal with both approaches and dependent on choice of ablation energy,<sup>305</sup> electrode and catheter design, interplay of biophysical response characteristics of targeted tissue and its related anatomy,<sup>306, 307</sup> including variation in atrial wall thickness regionally (thickest at the roof, mitral isthmus and left lateral ridge<sup>308</sup>) and

between individuals (posterior wall 0.9 to 7.4 mm in one study),<sup>309</sup> atrial and pulmonary venous morphology<sup>257, 310, 311</sup> and associated vasculature.<sup>257</sup> The published hybrid ablation experience has thus far exclusively incorporated radiofrequency ablation (Table 2), which relies on current flow alternating at radiofrequency causing resistive tissue heating and depends fundamentally on electrode-tissue contact.<sup>312, 313</sup> Additional variables affecting lesion depth include power and duration of ablation,<sup>314</sup> electrode size and orientation,<sup>315-317</sup> electrode tip cooling to prevent surface char and coagulum allowing for deeper lesions,<sup>318, 319</sup> electrical tissue impedance,<sup>314</sup> and tissue heat sinks.<sup>35, 306, 307, 320</sup> Monitoring electrode contact force, temperature rise, impedance fall, and electrogram diminution allows real-time monitoring of lesion evolution surrogates and safe ablation,<sup>313</sup> though none of these parameters obviate the need for confirming conduction block.<sup>29</sup>

Despite these measures, and documentation of block acutely, conduction may recover and whether this is from tissue regeneration or incomplete ablation and reversible injury is unknown.<sup>284</sup> The latter is supported by data demonstrating that common locations of late recovery after endovascular catheter ablation are sites with known difficulty in maintaining catheter tissue contact (close to the pulmonary veins, left lateral ridge, mitral isthmus, accessory pulmonary veins or a common left pulmonary vein ostium),<sup>50, 311, 321-323</sup> electroanatomical correlation of gaps with measured tissue contact force,<sup>322, 323</sup> echocardiography<sup>324</sup> and contrast MRI showing evidence of reversible injury with edema which resolves on serial scans<sup>205</sup> with recovery over days to weeks, and incomplete scarring at ablation sites with conduction recovery;<sup>203, 204</sup> and histological evidence of non-transmural lesions in pulmonary veins that reconnect late after PVI.<sup>325</sup> In addition, outcomes are better when areas with reversible injury are re-ablated once identified after a 60-90 minute wait period<sup>326</sup> and/or adenosine,<sup>326-328</sup> ablating to unexcitability as a superior tissue endpoint to conduction block,<sup>329</sup> measuring and maintaining tissue contact force to deliver more effective lesions,<sup>322, 330-332</sup> and visually identifying gaps after electroanatomically tagging ablation lesions.<sup>333, 334</sup>

The specific additional challenges with an epicardial approach include constraints from mediastinal anatomy and pericardial reflections<sup>335</sup> in accessing individual-specific arrhythmogenic triggers and substrate; the increased proximity and risk of collateral injury to great vessels, coronary arteries, lungs, mediastinum, esophagus, liver, diaphragmatic vessels, and phrenic nerves;<sup>335</sup> how well suited catheter design is for navigation, maintaining tissue contact over the smooth epicardial convexity of the beating heart and safe delivery of ablation energy; how well matched the selected ablation energy is for the local tissue environment and characteristics;<sup>305, 336</sup> how to overcome endoluminal and intramural arterial heat sinks,<sup>35, 306, 307, 320</sup> the presence of epicardial coronary vessels at key linear lesion sites (mitral and cavotricuspid isthmus), and presence of epicardial fat which limits energy delivery to underlying myocardium<sup>305, 306, 337</sup> as well as independently influencing AF pathophysiology and recurrence after endocardial ablation.<sup>338</sup>

To overcome these challenges, minimally invasive surgical approaches have incorporated versatile access and catheter designs to facilitate controlled tissue manipulation and ablation. The bipolar radiofrequency clamp (Atricure, West Chester, OH) which is utilized for PVI with the bilateral thoracoscopic hybrid approach has favorable preclinical results,<sup>36, 339</sup> though a variable number

Table 3: Systematic Review of Hybrid Ablation Studies – Outcomes

First Author	No. patients	AF type: PAF/ PAF/LSP/AF	Procedure time (min)	Hospital stay (days)*	Death (N)	Death or Major Complication (N)	Acute non-fatal thromboembolism (N)	Major Surgical Complications (non-embolic, non fatal) (N)	No. with minimum 12-month FU	Confirmation of AF recurrence	12-month AAD-free SR maintenance – All (N)	12-month AAD free FU for PAF	12-month AAD free FU for PAF/LSP/AF
Thoracoscopic Clamp-based Approach													
Mahapatra <sup>57</sup>	15	0/9/6	Both components: mean 450±20	median 5.0 (IQR 5.0–5.5)	0	0	0	None	14	7 day event monitor, AF >30 secs	13/14	78.3%	88.2%
Lee <sup>66</sup>	7	NA	NA	median 5 (IQR 4-6)*	0	1	0	1 prolonged ventilation postop*	NA	Continuous ECG monitoring (duration and criteria not stated) or pacemaker/ICD monitoring	(12/23)\$	NA	NA
Pison <sup>33</sup>	26	15/10/1	Both components: mean 280±84	mean 7±2	0	2	0	1 pleural effusion requiring drainage, 1 surgical incision pain prolonging hospital stay	24	7-day Holter monitoring, AF/AT >30 secs	20/24	11/15	10/11
La Mei <sup>62</sup>	35	16/8/11	Both components: median 268 (IQR 186–477)	median 3.4 (IQR 2.6–4.1)	0	0	0	None	35	7 day Holter, AF/AT >30 secs	32/35	14/16	16/19
Kurfirst <sup>63</sup>	30	0/0/30	Surgical component: mean 210±30	mean 4.5±3	0	5	0	2 left pulmonary artery bleeding requiring sternotomy, 2 phrenic nerve palsies persistent at 12 months, 1 tamponade postop day 24 with overanticoagulation	0	7 day Holter, AF/AT >30 secs	(27/30 at mean 208±29 days)	-	(27/30 at mean 208±29 days)
Lee <sup>64</sup>	10	1/0/9	Surgical component: mean 221	median 12	0	3	1 stroke	1 reexpansion pulmonary edema and pneumonia, 1 pericardial effusion	0	Holter (duration not specified) AF/AT >30 secs	(10/10 at median 7.6 months [range 6.7 - 11.6])	NA	NA
Pison <sup>65</sup>	78	29/34/15	NA	median 6 (IQR 5.5-8)	0	6	0	1 reoperation for bleeding, 1 bleeding not requiring reoperation, 2 pneumonia, 2 complete heart block requiring pacemaker implantation	78	7 day Holter, AF/AT >30 secs	68/78	22/29 (76%)	43/49
Thoracoscopic Encircling Catheter - based Approach													
La Mei <sup>69</sup>	19	5/4/10	Both components: median 216 (IQR 132–391)	median 3.6 (IQR 2.7–4.3)	0	0	0	None	19	7 day Holter, AF/AT >30 secs	7/19	3/5	4/14
Bisler <sup>60</sup>	45	0/0/45	Epicardial component: mean 85±9	mean 3.9±1.4	0	0	0	None	45	ILR, AF>5 min or overall AF burden >0.5%	40/45	-	40/45
Subxiphoid Convergent Approach													
Geh <sup>61</sup>	101	17/37/47	NA	mean 4.4	2#	7	1 TIA	2 retroperitoneal bleeding, 2 tamponade	69	24 hour Holter, AF/AT >30 secs	46/69	NA	NA
Gersak <sup>66</sup>	73	0/22/51	Surgical component: 1.12±38	NA	0	8	1 stroke	2 bleeding requiring sternotomy, 2 bleeding not requiring reoperation, 1 tamponade, 1 pericardial effusion, 1 pleural effusion	66	ILR (n=48/73) or Holter (24 hours or 7 days), criteria not stated	34/66	-	34/66

First Author	No. patients	AF type: PAF/PrAF/LSPPrAF	Procedure time (min)	Hospital stay (days)*	Death (N)	Death or Major Complication (N)	Acute non-fatal thromboembolism (N)	Major Surgical Complications (non-embolic, non fatal) (N)	No. with minimum 12-month FU	Confirmation of AF recurrence	12-month AAD-free SR maintenance - All (N)	12-month AAD free FU for PAF (N)	12-month AAD free FU for PrAF/LSPPrAF
TOTAL **	432	83/124/225			2	32	3	27	350		260	50	160
% of TOTAL					0.5%	7.4%	0.7%	6.3%	81.0%		74.3%	76.9%	73.4%

\* Excludes readmissions for delayed staged procedures; \*\* Excludes 7 patients reported by Lee et al 56 as results pooled with 18 patients undergoing non-hybrid minimally invasive AF surgery; \$Data for all minimally invasive patients including 7 with hybrid and 18 with non-hybrid surgical ablation, with 12 month follow-up; #1 sudden death, 1 death from atherosophageal fistula  
 PAF - Paroxysmal AF, PrAF - persistent AF, LSPPrAF - long-standing persistent AF; NA - not available

of repeat applications (at least 3 and often more in clinical studies<sup>29, 31</sup>) are required to achieve block and reconnection gaps are increasingly prevalent over time from none when tested immediately<sup>33, 65</sup> to 12.5% after 4 days<sup>64</sup> and 87% of right and 77% of left pulmonary veins at 3 months.<sup>63</sup> Bipolar sources have been reported to create better lesions than monopolar sources with epicardial ablation.<sup>340</sup> Additional linear lesions created with the bipolar radiofrequency pen (Atricure, West Chester, OH), which again has good preclinical efficacy data,<sup>34, 341</sup> resulted in reconnection gaps in 14-36% of box lesions at immediate staged endovascular testing,<sup>62, 65</sup> 27% of roof and mitral isthmus lines at 4.3±1.3 days,<sup>57</sup> and 63% of roof and 40% of inferior lines at 3 months<sup>63</sup> even when bidirectional block was confirmed during epicardial ablation. To overcome limitations in mitral isthmus linear ablation from attempts to avoid coronary arterial injury,<sup>58</sup> some investigators connected the left fibrous trigone to the mitral annulus.<sup>29</sup> However, whether this has similar efficacy and propensity to disrupt focal drivers or reentrant flutters is unknown. Similarly, ablation lines across Bachmann bundle are hard to establish due to atrial thickness and results in inter-atrial dyssynchrony.<sup>63</sup> The bilateral thoracoscopic approach additionally allows visualized access to the epicardial ganglia, ligament of Marshall, and left atrial appendage, can protect or maneuver away from critical anatomical structures, but requires collapsing the lung and opening the pericardium on each side.

The right-sided thoracoscopic approach and convergent (posterior pericardioscopic) approaches utilize specially designed linear ablation monopolar RF catheters incorporating suction to increase tissue contact and optimize catheter stability (Estech Cobra Adhere XL, Atricure, West Chester, OH, and Numeris Guided Coagulation System with VisiTrax, nContact Surgical, Inc, Morrisville, NC, USA, respectively), allowing for less invasive access than the bilateral thoracoscopic approach. Both of these catheters performed less well than the bipolar clamp in preclinical studies.<sup>34</sup> However, with the encircling suction catheter (Estech Cobra Adhere XL), when applications were repeated until entrance and/or exit block in conduction to/ from the posterior left atrium, block was maintained after 1 month at endovascular in all with bidirectional block and 25% with unidirectional block at epicardial ablation.<sup>60</sup> In contrast, when block is not tested for during epicardial application, almost all had conduction gaps during immediate-staged endovascular study.<sup>59</sup> The ablation line also abolished standardized ganglionic responses except at the right inferior ganglion, which was located outside the box lesion.<sup>59</sup> A limitation with the unilateral right-sided approach is lack of access to the left atrial appendage. The convergent approach avoids thoracoscopy altogether, utilizing laparoscopy to guide subdiaphragmatic posterior pericardioscopy.<sup>55, 68</sup> Space constraints limits placement of additional catheters for simultaneous electrophysiological monitoring and,

although inferior and posterior left atrial surfaces are well visualized, the superior and anterior lesions need to be made without direct visualization and rely on knowing catheter angulation and orientation. Pericardial reflections lead to discontinuous lesions at both superior and right inferior pulmonary veins, necessitating routine endocardial touch-up lesions at these sites, whilst access to the ligament of Marshall, appendage and ganglia is limited and the esophagus is left more vulnerable than with the bilateral thoracoscopic approach.<sup>55, 68</sup> Although the other hybrid approaches have isolated the posterior left atrium, the convergent approach has focused on debulking this region. There are no data comparing the two approaches directly.

When electroanatomical mapping was not utilized to register lesions during epicardial ablation, techniques to correlate with the endovascular component during immediate staging involved leaving the epicardial ablation catheter in situ to correlate fluoroscopically or gently prodding epicardially at the ablation line whilst correlating endocardial catheter position with intravascular ultrasound.

### Electrophysiological Perspective 5 – Cardiac Autonomic Ganglia as Targets during Atrial Fibrillation Ablation

An autonomic etiology for AF was first recognized with description of vagally-induced AF in 1978.<sup>342</sup> Pulmonary vein isolation has reduced efficacy in treating paroxysmal vagotonic AF,<sup>80</sup> whereas atrial vagal denervation can abolish it.<sup>88</sup> The importance of autonomic influences on AF is also evident from a reduction in AF recurrence following antral PVI when vagal responses (bradycardia, atrioventricular block, hypotension) are fortuitously elicited during radiofrequency ablation and abolished,<sup>81</sup> the increase in late AF recurrence in those with high serum titres of autoantibodies against the beta-1 adrenoceptor and M2 muscarinic receptor at the time of cryoballoon PVI,<sup>96</sup> and in the post cardiac transplantation population, whose denervated recipient hearts are relatively resistant to AF with 70% lower AF incidence than matched patients undergoing cardiac surgery with left atrial maze.<sup>90</sup>

The atria are richly innervated by autonomic nerves<sup>343</sup> and between 700-1500 epicardial ganglionated autonomic neuronal plexi are associated with the heart, though numbers decline by up to 50% with age, with complex circuits involving both parasympathetic and sympathetic components.<sup>344</sup> The atrial ganglia are primarily clustered at the superior right atrium, superior left atrium, posterior right atrium, posteromedial left atrium, and the inferolateral aspect of the posterior left atrium.<sup>344</sup> Following the demonstration in dogs that ganglionic stimulation induces calcium-mediated pulmonary vein triggers<sup>345</sup> and enhances trigger-induction of AF, with the opposite effects with ganglionic block,<sup>292</sup> studies began to focus on modifying local autonomic atrial input by targeting epicardial ganglia to improve outcomes of

catheter AF ablation<sup>82</sup> and surgical maze.<sup>346</sup> After validation of the technique in dog experiments, eliciting bradycardic responses and atrioventricular block at sites of high frequency atrial burst pacing has been used to map ganglionic cluster sites from the endocardium<sup>82</sup> with descriptions of five common left atrial sites (superior left, inferior left, ligament of Marshall, anterior right, inferior right).<sup>86</sup> Although some ganglionic sites may not elicit such a response yet still exert modulatory influence,<sup>84</sup> whilst surgical approaches are able to directly visualize these ganglia, elimination of the high frequency stimulation response may serve as a useful ablation end-point. Such ganglionic responses were shown to be present in 86% of 216 patients after antral PVI and predicted arrhythmia recurrence in patients with paroxysmal AF (51 vs 8% at >6 months) but not persistent AF (40 vs 39%), even though a higher proportion of persistent AF patients had positive ganglionic responses.<sup>94</sup> Ganglia may also co-localize with CFAE although the mechanism is not fully explained.<sup>83, 85, 86</sup>

There is currently no consensus on whether to routinely perform ganglion ablation during catheter ablation of AF.<sup>347</sup> A meta-analysis of six randomized trials (342 patients) concluded that ganglion ablation improves the results of catheter PVI or surgical maze in reducing freedom from AF recurrence, but as standalone therapy the outcome is inferior to PVI,<sup>348</sup> with similar results in a recent trial of 242 patients with paroxysmal AF (at 2 years, freedom from recurrence 74 vs 56 vs 46%, respectively).<sup>92</sup> In persistent AF, even though retained ganglionic responses after antral PVI may not predict AF recurrence,<sup>94</sup> trials of ganglionic ablation during both catheter ablation<sup>91</sup> and surgical maze<sup>346</sup> have reported positively on efficacy. Long-term outcomes are unknown, with dog data demonstrating the reappearance of ganglionic responses with time,<sup>349</sup> presumably due to axonal regrowth, whilst isolated ganglionic ablation (i.e. without PVI) may be paradoxically proarrhythmic.<sup>350</sup>

### Electrophysiological Perspective 6 – Stroke Prevention and Left Atrial Appendage Closure

Stroke mechanisms in AF are complex and demonstrating a role for fibrillation independent to atrial myopathy and vascular disease is challenging as both not only predispose to AF but also to stroke risk with AF.<sup>351</sup> There are at present no randomized data demonstrating that AF ablation, whether surgical or catheter-based, reduces stroke risk. Although Cox et al reported a low incidence of stroke (0.7%) after the cut-and-sew maze procedure in 265 patients followed for 11.5 years,<sup>352</sup> the majority had low stroke risk at baseline and the study was non-randomized. The PRAGUE-12 trial randomized 224 patients undergoing cardiac surgery to concomitant maze or no maze, and reported 1-year stroke rates of 2.7 vs. 4.3% (p=0.319).<sup>239</sup> Overly aggressive atrial compartmentalization and debulking may paradoxically increase stroke risk by rendering the atrium without contractile activity despite restoration of sinus rhythm, mitigating any benefit.<sup>353</sup> In a large, unselected catheter ablation cohort, 2% developed stroke after 1,347 patient-years follow-up, with no significant difference when sinus rhythm was maintained, though the study was probably underpowered as most patients had low baseline stroke risk.<sup>175</sup> A study of 4,212 patients who underwent AF ablation reported reduced risk of stroke, death and dementia compared to 16,848 age-gender matched controls with AF but no ablation, with similar rates to 16,848 age-gender matched controls without AF.<sup>354</sup> The results of the CABANA trial (clinicaltrials.gov/NCT00911508), which aims to study the effects of catheter ablation

on mortality, stroke and bleeding as compared to drug therapy, are awaited.

Recent advances in cardiac imaging have allowed an appreciation that morphological complexity of the LAA significantly influences thromboembolic risk, supporting a structural approach to thromboprophylaxis.<sup>355</sup> The efficacy of this approach was demonstrated by the WATCHMAN trial of percutaneous LAA occlusion.<sup>356</sup> A meta-analysis of 7 studies including 3,653 patients undergoing appendage closure (n = 1716) versus not (n = 1937) at the time of cardiac surgery reported a significantly reduced stroke incidence with closure (0.95 vs 1.9% at 30 days, 1.4 vs 4.1% at last follow-up) and reduced mortality (1.9 vs 5%).<sup>357</sup> Surgical approaches, however, have been limited by incomplete closure, with surgical amputation and oversewing yielding highest maintained closure rates.<sup>351</sup> Results of the LAAOS III trial (clinicaltrials.gov/NCT01561651), which plans to randomize 4,700 patients undergoing cardiac surgery to LAA occlusion or no occlusion, are awaited. A number of minimally invasive approaches have been developed, using either suture or clip exclusion or staple excision, though none have yet been proven to reduce stroke.<sup>351</sup> In addition, LAA exclusion may not be regarded as a panacea for stroke reduction in AF, as vascular mechanisms may coexist and thrombi are more likely to be extra-appendicular in valvular AF patients.<sup>358</sup> There are also hemodynamic sequelae which are in keeping with loss of its compliance and atrial booster function.<sup>359, 360</sup> In addition to modulating stroke risk, appendage ligation or excision results may serve as a form of substrate modification<sup>361</sup> by reducing atrial mass<sup>118</sup> and eliminating appendage triggers and drivers,<sup>362, 363</sup> whereas electrical isolation without mechanical closure may paradoxically increase stroke risk through appendage blood stagnation.<sup>364</sup>

### Electrophysiological Perspective 7 – Hemodynamic Impact of Atrial Fibrillation Ablation

In the majority of individuals, restoration of sinus rhythm with ablation leads to significant improvement in left ventricular function, effects that extend beyond rate control,<sup>11, 365, 366</sup> even when baseline ejection fraction is normal,<sup>367</sup> with improvements also reported after surgical maze.<sup>368</sup> Restoration and maintenance of sinus rhythm results in reverse atrial remodeling<sup>8, 369, 370</sup> and similar effects are seen after surgical maze,<sup>371</sup> although with time these effects can subsequently reverse<sup>372</sup> and it is unclear whether this is due to the maze procedure itself or persistent risk factors leading to progressive atrial myopathy. Without the expected benefits of reverse atrial remodeling from immediate restoration of sinus rhythm, such as those with paroxysmal AF and low arrhythmia burden, a reduction in atrial contractile function is seen after maze, more so with more extensive ablation (new left atrial dysfunction 8.5% after PVI compared to 30% after additional linear ablation).<sup>373</sup> Surgical maze may result in reduced atrial compliance which can cause severe, symptomatic pulmonary hypertension (“stiff left atrial syndrome”).<sup>374</sup> This has also been reported after catheter ablation in 1.4% of 1,380 patients, predisposing factors being smaller pre-procedural left atrial size (≤45mm), preexisting left atrial hypertension, increased baseline left atrial fibrosis, diabetes mellitus and obstructive sleep apnea.<sup>375</sup>

### Electrophysiological Perspective 8 – Critical Appraisal of the Role of Hybrid Ablation in Improving Outcomes from Atrial Fibrillation Ablation

**Outcome from Hybrid Ablation of Atrial Fibrillation: Results of**

### Systematic Review

Published success rates from hybrid ablation (Table 3), defined as maintained sinus rhythm off antiarrhythmic medications at 12 months, are 74.3% overall (data available for 81% [350/432]), 76.9% for paroxysmal (data available for 76% [65/83]) and 73.4% for persistent / long-standing persistent AF patients (data available for 62% [218/349]). Methods used to detect recurrence varied from a 24-hour Holter monitoring at prespecified follow-up intervals to continuous ECG monitoring using implantable loop recorders or pacemakers and defibrillators (Table 3). Success rates differed significantly among the three approaches (Table 3), with highest rates reported with the bilateral thoracoscopic clamp-based approach (88.1% [133/151]), intermediate with the unilateral thoracoscopic suction encircling catheter-based approach (73.4% [47/64]) and lowest with the convergent approach (59.3% [80/135]),  $p < 0.001$ ). The difference in the proportion of patients with long-standing persistent AF (37% [72/205]), 86% [55/64] and 56% [98/174] respectively,  $p < 0.001$ ) may partly account for some of this difference in outcome (Table 3). However, when data were available, success rates in patients with persistent and long-standing persistent AF were similar to overall success rates (88.2% [82/93], 74.6% [44/59] and 51.5% [34/66] respectively,  $p < 0.001$ ). There was limited separately reported 12-month data for paroxysmal AF patients (78.2% [47/60], 60.0% [3/5], no data for convergent procedure,  $p = 0.325$ ).

Major complications (Table 3) were death ( $n = 2$ , both with convergent approach), thromboembolic ( $n = 3$ , of which 2 were with convergent approach, none fatal) and non-thromboembolic complications ( $n = 27$ ), consisting of 10 thoracic or retroperitoneal bleeds with or without rescue sternotomy, 6 tamponade/pericardial effusion, 2 complete heart block requiring pacemaker implantation, 2 phrenic nerve palsy, 2 pleural effusion, 4 respiratory complications and 1 with incisional pain delaying hospital discharge. Rate of death or non-fatal major complications were 7.4% overall, 8.5% with the bilateral thoracoscopic clamp-based approach, 0% with the thoracoscopic suction encircling catheter-based approach and 8.6% with the convergent approach (Table 3). Average length of hospital stay, when reported, was between 3.6 and 7 days (average for the three different approaches 5.6 vs. 3.8 vs. 4.4 days respectively, Table 3).

### Hybrid Ablation vs. Sequential Catheter Ablation

For endovascular catheter ablation of paroxysmal AF, 18-month freedom from arrhythmia recurrence and antiarrhythmics was reported in 75% of 9,590 patients in a worldwide survey of 182 centers from 24 countries treated between 2004-6.<sup>376</sup> Results at 5 years are 47-78% after the first procedure<sup>99, 176, 177</sup> and 75-92% after repeat procedures.<sup>99, 100, 176, 177</sup> In most cases, recurrence is due to recovered conduction at a prior ablation site.<sup>99, 177</sup> A 12- to 24-month success rate of 73-92% has been reported from contemporary catheter ablation techniques to prevent late reconnection of pulmonary veins, which include using a force-sensing catheter (SmartTouch, Biosense Webster, Inc., Diamond Bar, CA) to ensure adequate contact force during ablation, a second generation cryoballoon catheter designed for better contact and surface temperature distribution (Arctic Front Advance, Medtronic, Minneapolis, MN), using failure to capture as an ablation endpoint, and incorporating a wait period and adenosine to identify reversible injury and unmask latent conduction.<sup>326, 329, 331, 377-379</sup> It is unknown whether these strategies will be subject to similar rates of late attrition in success seen with earlier approaches.<sup>177</sup>

With persistent and long-standing persistent AF, endovascular catheter ablation yield sinus rhythm maintenance off antiarrhythmic medication in 35-77% at 12 months after a single procedure<sup>122, 129, 238, 240, 242</sup> and 64-79% at 18-24 months after repeat procedures.<sup>129, 242, 243, 376</sup> Patients with persistent and long-standing persistent AF have a higher rate of late attrition than with paroxysmal AF,<sup>380</sup> with reported 5 year success rates of 45-81%.<sup>99, 129, 381, 382</sup>

Complications of endovascular catheter AF ablation were seen in 6.3% of an estimated 93,801 procedures performed between 2000-10 in the National Inpatient Sample database.<sup>383</sup> Complications were cardiac in 2.5%, including 1.5% pericardial and 0.3% requiring rescue cardiac surgery, respiratory in 1.3%, postoperative hemorrhage in 3.4%, vascular complications in 1.5%, and neurological (thromboembolic) in 1%. In-hospital mortality was 0.5%. In the California State Inpatient Database, complications after first AF ablation between 2005-8 were seen in 5% of 4,156 patients, most commonly vascular.<sup>384</sup> The world-wide survey reported major complications in 4.5% of 20,825 catheter ablation procedures on 16,309 patients between 2003-6.<sup>376</sup> Complication rates were low in other large cohorts with patients undergoing multiple procedures (3.3% of 1,404 patients, 20% had repeat ablation;<sup>99</sup> 5.2% of 1,220 patients, 27% had repeat ablation<sup>176</sup>). Rates of pulmonary vein stenosis are 0.3-1.3% and atrio-esophageal fistula are 0-0.04%.<sup>99, 176, 376</sup> Studies reporting on the second generation cryoballoon ablation have reported higher rates of right phrenic nerve palsy (3.5-5.6%) than catheter radiofrequency ablation.<sup>378, 379</sup> Cost-effectiveness analyses of endovascular catheter ablation in various developed countries' healthcare models have demonstrated reasonable cost-effectiveness in patients who have paroxysmal AF, with improved quality of life and avoidance of future health care costs,<sup>385, 386</sup> including when utilized as a first-line approach in younger patients,<sup>387</sup> although are sensitive to AF recurrence rates and impact on stroke risk.<sup>388-393</sup>

The FAST trial compared bilateral thoracoscopic epicardial ablation to endovascular catheter ablation, randomizing 124 patients with drug-refractory non-valvular AF (67% paroxysmal, 33% persistent, CHADS<sub>2</sub> of 0 or 1 in 90%) to either surgical PVI using a bipolar radiofrequency clamp with intraoperative confirmation of block, LAA staple excision, ganglionated plexi ablation, ligament of Marshall transection and optional additional linear ablation (31%), or endovascular antral radiofrequency PVI with optional additional linear ablation (50%).<sup>394</sup> More patients in the surgical group were free from recurrent atrial arrhythmia off antiarrhythmics at 12 months (overall: 66 vs 37%,  $p = 0.002$ ; paroxysmal AF: 69 vs 35%,  $p = 0.005$ ; persistent AF: 56 vs 36%,  $p = 0.341$ ). It is unclear whether the difference in success was due to more durable lesions or the more diverse ablation targets with surgical ablation, but the results should be interpreted in light of the higher proportion with persistent AF in the endovascular catheter ablation group (41 vs 21%) and lower success rate of catheter ablation in comparison to the published contemporary data above, particularly with paroxysmal AF. There were more frequent procedural complications (23 vs 3.2%) and fewer thromboembolic events at 12 months (0/61 vs 2/63), with surgical ablation preventing an arrhythmia recurrence for every 3.4 and causing an additional complication for every 5.1 procedures.<sup>394</sup> The procedural complication rate was higher than that of the published hybrid ablation literature summarized above (7.4%).

To compare hybrid ablation with repeat catheter ablation, Mahapatra et al<sup>57</sup> matched their hybrid ablation group of 15

persistent and long-standing persistent AF patients to a control group of 30 long-standing persistent AF patients undergoing repeat catheter ablation, matching for left atrial size, duration and type of AF, lack of prior cardiac surgery, left ventricular ejection fraction and use of antiarrhythmic medications. The hybrid group had bilateral thoracoscopic clamp-based approach with delayed staged endovascular ablation at  $4.3 \pm 1.3$  days, multiple linear ablation sets, ganglion ablation, ligament of Marshall ablation, LAA excision, coronary sinus ablation and CFAE ablation. The catheter ablation group all had antral isolation, roof line, cavotricuspid isthmus line and optional mitral isthmus line (17 cases), coronary sinus ablation (9 cases), SVC isolation (11 cases) and CFAE ablation (12 cases). After a mean follow-up of 21 months, 87% (13/15) of hybrid ablation and 53% (16/30) of catheter-alone patients were free of atrial arrhythmia off antiarrhythmics. Repeat ablation was performed in 0/15 hybrid ablation and 3/30 catheter-alone patients.

In summary, the fundamental principle underlying hybrid ablation in assessing the electrophysiological effects of lesions and ensuring that targets are ablated to specific endpoints to improve outcomes is incontrovertible. However, there is limited evidence supporting the concept that a multidimensional intervention targeting all possible arrhythmia mechanisms for all patients in the same sitting will result in superior results, even when these lesions are reinforced from both epicardial and endocardial sides to maximize the chances of sustained conduction block. Hybrid ablation procedures are associated with increased complications and longer post-procedural hospital stay, whilst cost-effectiveness studies have been limited by the lack of long-term outcome data.<sup>395</sup> Studies directly comparing hybrid with endovascular catheter ablation have had small numbers, differences in patient characteristics and ablation targets, variable periprocedural antiarrhythmic and anticoagulant management, different methods for identifying recurrence arrhythmia, and have not incorporated recent advances in endovascular ablation practice offering more durable lesions or better identifying individual-specific mechanistic targets, an understanding of which has implications on long-term tailored approaches. Outcome data from contemporary endovascular catheter approaches suggest similar success rates to hybrid ablation, both for paroxysmal and persistent patient groups, particular when repeat catheter ablations are accounted for. When considering the hybrid approach, matching intervention to mechanism is key for identifying targets, ablation endpoints, and the specific advantage over the endovascular approach for the patient at hand, balanced against the increased procedural complexity, more complications some of which are life-threatening, and longer hospital stay.

#### Hybrid Ablation vs. Cut-and-Sew Maze

Since the first description of the ablation-assisted open surgical maze yielding similar short-term outcomes to the traditional cut-and-sew technique, 5 others have reported that the traditional approach yields superior long-term outcomes, with hazard ratio for recurrent arrhythmia of 0.40 up to 5 years and 0.23 beyond 5 years.<sup>396</sup> In a meta-analysis of 16 randomized trials, the cut-and-sew approach was associated with higher sinus rhythm prevalence and lower stroke rates outcome compared to ablation-assisted approaches.<sup>397</sup> Lee et al compared 25 hybrid ablation patients (bilateral thoracoscopic clamp-based) to 38 cut-and-sew maze patients and reported 1 year freedom from AF and antiarrhythmic medication in 52% and 87.5%, respectively ( $p=0.004$ ), even though the cut-and-sew group had more with long-standing persistent AF (40 vs 16%).<sup>56</sup>

However, in their hybrid group, only 7 patients followed through with the endovascular catheter ablation component. There were more frequent complications in the cut-and-sew group (18 vs 4%). A systematic review comparing minimally invasive endocardial Cox-maze, minimally invasive epicardial ablation and hybrid ablation reported operative mortality at 0%, 0.5% and 0.9%; perioperative permanent pacemaker implantation in 3.5%, 2.7% and 1.5%, rescue median sternotomy in 0%, 2.4% and 2.5%, reoperation for bleeding in 1.0%, 1.5% and 2.2%, mean length of stay of 5.4, 6.0 and 4.6 days, and 12-month maintenance of sinus rhythm off antiarrhythmics in 87%, 72% and 71%, respectively.<sup>28</sup>

#### Immediate vs. Delayed Staged Hybrid Ablation

There is limited published data allowing direct comparison of immediate to delayed staging of the endovascular component of hybrid ablation. Immediate staging requires a laboratory hosting both surgical and electrophysiological setups, careful management of intraprocedural anticoagulation with transeptal and endoscopic accesses, and the available time and resources to complete both interventions in the same sitting. Delayed staging, where endovascular testing and ablation has been performed days to months after minimally invasive epicardial ablation, allows healing of the surgical wounds and time for reversible injury from ablation to abate and reconnections to establish, and has been shown to increase the likelihood of discovering PV reconnection during endocardial mapping versus a same day procedure (48% vs 14%).<sup>398</sup> It can be performed in separate surgical and electrophysiological laboratory setups. Patients may prefer a procedure where both components are completed in the same sitting or during the same hospitalization.

#### Future Directions

Atrial fibrillation ablation offers considerable benefits to patients towards symptom control and quality of life improvement.<sup>75</sup> The multiplicity and progressive nature of AF mechanisms and recovery of conduction may account for progressive attrition in maintaining sinus rhythm with long-term follow-up.<sup>129, 380</sup> The pioneering developments that have led to the various hybrid ablation approaches are an opportunity in properly selected patients without having to recourse to open heart surgery. The choice of procedural approach utilized for hybrid ablation is important, given the difference in possible lesion sets, success rates, complications, adjunctive LAA closure and access to adjunctive ablation targets. However, randomized trial data are lacking and long-term efficacy is unproven. The PRHACA (Prospective, Randomized Comparison of Hybrid Ablation vs. Catheter Ablation) trial ([clinicaltrials.gov/NCT02344394](http://clinicaltrials.gov/NCT02344394)) is an investigator sponsored trial which is currently recruiting patients with persistent AF to test the nContact system (convergent approach). The CONVERGE (Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation) trial ([clinicaltrials.gov/NCT01984346](http://clinicaltrials.gov/NCT01984346)) is an industry sponsored trial which is also recruiting persistent AF patients to test the nContact system. The SCALAF trial ([clinicaltrials.gov/NCT00703157](http://clinicaltrials.gov/NCT00703157)), which aims to compare efficacy of minimally invasive surgical and catheter-based PVI, is underway. Another active trial ([clinicaltrials.gov/NCT02392338](http://clinicaltrials.gov/NCT02392338)) is comparing hybrid ablation with minimally invasive thoracoscopic ablation alone in persistent AF.

A promise of progress comes from an improved understanding of how anatomical substrate relates to electrophysiological observations, better catheters and mapping technologies, novel energy sources, adequate management of recurrences, and identifying and treating

underlying clinical risk factors. Whether hybrid ablation will add to this remains to be seen. In the absence of robust efficacy data, and given the increased risk of complications, associated morbidity and length of hospital stay as compared to catheter ablation, caution should be exercised in adopting this approach universally. The present data suggest that, perhaps, with appropriate patient selection, accurate identification of patient-specific mechanisms and targets, and selection of optimal access to maximize anatomical vantage to these targets, this novel approach may have a role in specific situations. It may be better suited as a concomitant procedure during cardiac surgery for other reasons, for example patients requiring thrombectomy or LAA closure. Alternatively, it may help translate novel therapeutic pathways to practice, such as controlled delivery of genetic vectors influencing arrhythmia mechanisms<sup>399-401</sup> or humeral mediators governing response to injury.<sup>402-404</sup>

## References

- Cox JL, Boineau JP, Schuessler RB, Ferguson TB, Jr., Cain ME, Lindsay BD, Corr PB, Kater KM, Lappas DG. Successful surgical treatment of atrial fibrillation. Review and clinical update. *Jama* Oct 9 1991;266:1976-1980.
- Cox JL, Schuessler RB, D'Agostino HJ, Jr., Stone CM, Chang BC, Cain ME, Corr PB, Boineau JP. The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. *The Journal of thoracic and cardiovascular surgery* Apr 1991;101:569-583.
- Gaynor SL, Schuessler RB, Bailey MS, Ishii Y, Boineau JP, Gleva MJ, Cox JL, Damiano RJ, Jr. Surgical treatment of atrial fibrillation: predictors of late recurrence. *The Journal of thoracic and cardiovascular surgery* Jan 2005;129:104-111.
- Weimar T, Schena S, Bailey MS, Maniar HS, Schuessler RB, Cox JL, Damiano RJ, Jr. The Cox-maze procedure for lone atrial fibrillation: a single-center experience over 2 decades. *Circulation Arrhythmia and electrophysiology* Feb 2012;5:8-14.
- Gaynor SL, Diodato MD, Prasad SM, Ishii Y, Schuessler RB, Bailey MS, Damiano NR, Bloch JB, Moon MR, Damiano RJ, Jr. A prospective, single-center clinical trial of a modified Cox maze procedure with bipolar radiofrequency ablation. *The Journal of thoracic and cardiovascular surgery* Oct 2004;128:535-542.
- Gammie JS, Haddad M, Milford-Beland S, Welke KF, Ferguson TB, Jr., O'Brien SM, Griffith BP, Peterson ED. Atrial fibrillation correction surgery: lessons from the Society of Thoracic Surgeons National Cardiac Database. *The Annals of thoracic surgery* Mar 2008;85:909-914.
- Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. *Jama* Jun 1 2005;293:2634-2640.
- Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. *The New England journal of medicine* Mar 2 2006;354:934-941.
- Jais P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. *Circulation* Dec 9 2008;118:2498-2505.
- Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O, Pehrson S, Englund A, Hartikainen J, Mortensen LS, Hansen PS. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. *The New England journal of medicine* Oct 25 2012;367:1587-1595.
- Jones DG, Halder SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, McDonagh TA, Underwood SR, Markides V, Wong T. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. *Journal of the American College of Cardiology* May 7 2013;61:1894-1903.
- Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, Sterns LD, Beresh H, Healey JS, Natale A. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. *Jama* Feb 19 2014;311:692-700.
- Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). *Circulation Arrhythmia and electrophysiology* Feb 2014;7:31-38.
- Pak HN, Hwang C, Lim HE, Kim JS, Kim YH. Hybrid epicardial and endocardial ablation of persistent or permanent atrial fibrillation: a new approach for difficult cases. *Journal of cardiovascular electrophysiology* Sep 2007;18:917-923.
- Kottkamp H, Hindricks G, Autschbach R, Krauss B, Strasser B, Schirdewahn P, Fabricius A, Schuler G, Mohr FW. Specific linear left atrial lesions in atrial fibrillation: intraoperative radiofrequency ablation using minimally invasive surgical techniques. *Journal of the American College of Cardiology* Aug 7 2002;40:475-480.
- Salenger R, Lahey SJ, Saltman AE. The completely endoscopic treatment of atrial fibrillation: report on the first 14 patients with early results. *The heart surgery forum* 2004;7:E555-558.
- Wolf RK, Schneeberger EW, Osterday R, Miller D, Merrill W, Flege JB, Jr., Gillinov AM. Video-assisted bilateral pulmonary vein isolation and left atrial appendage exclusion for atrial fibrillation. *The Journal of thoracic and cardiovascular surgery* Sep 2005;130:797-802.
- Beyer E, Lee R, Lam BK. Point: Minimally invasive bipolar radiofrequency ablation of lone atrial fibrillation: early multicenter results. *The Journal of thoracic and cardiovascular surgery* Mar 2009;137:521-526.
- Edgerton JR, Jackman WM, Mack MJ. A new epicardial lesion set for minimal access left atrial maze: the Dallas lesion set. *The Annals of thoracic surgery* Nov 2009;88:1655-1657.
- Han FT, Kasirajan V, Kowalski M, Kiser R, Wolfe L, Kalahasty G, Shepard RK, Wood MA, Ellenbogen KA. Results of a minimally invasive surgical pulmonary vein isolation and ganglionic plexi ablation for atrial fibrillation: single-center experience with 12-month follow-up. *Circulation Arrhythmia and electrophysiology* Aug 2009;2:370-377.
- Kiser AC, Cockfield W. Paracardioscopic ex-maze procedure for atrial fibrillation. *Multimedia manual of cardiothoracic surgery : MMCTS / European Association for Cardio-Thoracic Surgery* Jan 1 2010;2010:mmcts 2008 003863.
- Ad N, Suri RM, Gammie JS, Sheng S, O'Brien SM, Henry L. Surgical ablation of atrial fibrillation trends and outcomes in North America. *The Journal of thoracic and cardiovascular surgery* Nov 2012;144:1051-1060.
- Khargi K, Hutten BA, Lemke B, Deneke T. Surgical treatment of atrial fibrillation; a systematic review. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery* Feb 2005;27:258-265.
- Moten SC, Rodriguez E, Cook RC, Nifong LW, Chitwood WR, Jr. New ablation techniques for atrial fibrillation and the minimally invasive cryo-maze procedure in patients with lone atrial fibrillation. *Heart, lung & circulation* 2007;16 Suppl 3:S88-93.
- Damiano RJ, Jr., Schwartz FH, Bailey MS, Maniar HS, Munfakh NA, Moon MR, Schuessler RB. The Cox maze IV procedure: predictors of late recurrence. *The Journal of thoracic and cardiovascular surgery* Jan 2011;141:113-121.
- Ad N, Henry L, Friehling T, Wish M, Holmes SD. Minimally invasive stand-alone Cox-maze procedure for patients with nonparoxysmal atrial fibrillation. *The Annals of thoracic surgery* Sep 2013;96:792-798; discussion 798-799.
- Krul SP, Driessen AH, Zwinderman AH, van Boven WJ, Wilde AA, de Bakker JM, de Groot JR. Navigating the mini-maze: systematic review of the first results and progress of minimally-invasive surgery in the treatment of atrial fibrillation. *International journal of cardiology* Jun 5 2013;166:132-140.
- Je HG, Shuman DJ, Ad N. A systematic review of minimally invasive surgical treatment for atrial fibrillation: a comparison of the Cox-Maze procedure, beating-heart epicardial ablation, and the hybrid procedure on safety and efficacy. *European journal of cardio-thoracic surgery : official journal of the European*

- Association for Cardio-thoracic Surgery Jan 6 2015.
29. Lockwood D, Nakagawa H, Peyton MD, Edgerton JR, Scherlag BJ, Sivaram CA, Po SS, Beckman KJ, Abedin M, Jackman WM. Linear left atrial lesions in minimally invasive surgical ablation of persistent atrial fibrillation: techniques for assessing conduction block across surgical lesions. *Heart rhythm : the official journal of the Heart Rhythm Society* Dec 2009;6:S50-63.
  30. Kron J, Kasirajan V, Wood MA, Kowalski M, Han FT, Ellenbogen KA. Management of recurrent atrial arrhythmias after minimally invasive surgical pulmonary vein isolation and ganglionic plexi ablation for atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Apr 2010;7:445-451.
  31. Krul SP, Driessen AH, van Boven WJ, Linnenbank AC, Geuzebroek GS, Jackman WM, Wilde AA, de Bakker JM, de Groot JR. Thoracoscopic video-assisted pulmonary vein antrum isolation, ganglionated plexus ablation, and periprocedural confirmation of ablation lesions: first results of a hybrid surgical-electrophysiological approach for atrial fibrillation. *Circulation Arrhythmia and electrophysiology* Jun 2011;4:262-270.
  32. Gersak B, Kiser AC, Bartus K, Sadowski J, Harringer W, Knaut M, Wimmer-Greinecker G, Pernat A. Importance of evaluating conduction block in radiofrequency ablation for atrial fibrillation. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery* Jan 2012;41:113-118.
  33. Pison L, La Meir M, van Opstal J, Blaauw Y, Maessen J, Crijns HJ. Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. *Journal of the American College of Cardiology* Jul 3 2012;60:54-61.
  34. Schuessler RB, Lee AM, Melby SJ, Voeller RK, Gaynor SL, Sakamoto S, Damiano RJ, Jr. Animal studies of epicardial atrial ablation. *Heart rhythm : the official journal of the Heart Rhythm Society* Dec 2009;6:S41-45.
  35. Melby SJ, Zierer A, Kaiser SP, Schuessler RB, Damiano RJ, Jr. Epicardial microwave ablation on the beating heart for atrial fibrillation: the dependency of lesion depth on cardiac output. *The Journal of thoracic and cardiovascular surgery* Aug 2006;132:355-360.
  36. Melby SJ, Gaynor SL, Lubahn JG, Lee AM, Rahgozar P, Caruthers SD, Williams TA, Schuessler RB, Damiano RJ, Jr. Efficacy and safety of right and left atrial ablations on the beating heart with irrigated bipolar radiofrequency energy: a long-term animal study. *The Journal of thoracic and cardiovascular surgery* Oct 2006;132:853-860.
  37. Usui A, Inden Y, Mizutani S, Takagi Y, Akita T, Ueda Y. Repetitive atrial flutter as a complication of the left-sided simple maze procedure. *The Annals of thoracic surgery* May 2002;73:1457-1459.
  38. Kobza R, Kottkamp H, Dorszewski A, Tanner H, Piorkowski C, Schirdewahn P, Gerds-Li JH, Hindricks G. Stable secondary arrhythmias late after intraoperative radiofrequency ablation of atrial fibrillation: incidence, mechanism, and treatment. *Journal of cardiovascular electrophysiology* Nov 2004;15:1246-1249.
  39. Deneke T, Khargi K, Grewe PH, Calcum B, Laczkovics A, Keyhan-Falsafi A, Mugge A, Lawo T, Lemke B. Catheter ablation of regular atrial arrhythmia following surgical treatment of permanent atrial fibrillation. *Journal of cardiovascular electrophysiology* Jan 2006;17:18-24.
  40. Melby SJ, Lee AM, Zierer A, Kaiser SP, Livhits MJ, Boineau JP, Schuessler RB, Damiano RJ, Jr. Atrial fibrillation propagates through gaps in ablation lines: implications for ablative treatment of atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Sep 2008;5:1296-1301.
  41. Bertaglia E, Stabile G, Senatore G, Pratola C, Verlato R, Lowe M, Raatikainen P, Lamberti F, Turco P. Documentation of pulmonary vein isolation improves long term efficacy of persistent atrial fibrillation catheter ablation. *International journal of cardiology* Feb 1 2014;171:174-178.
  42. Ouyang F, Ernst S, Chun J, et al. Electrophysiological findings during ablation of persistent atrial fibrillation with electroanatomic mapping and double Lasso catheter technique. *Circulation* Nov 15 2005;112:3038-3048.
  43. Willems S, Steven D, Servatius H, Hoffmann BA, Drewitz I, Mullerleile K, Aydin MA, Wegscheider K, Salukhe TV, Meinertz T, Rostock T. Persistence of pulmonary vein isolation after robotic remote-navigated ablation for atrial fibrillation and its relation to clinical outcome. *Journal of cardiovascular electrophysiology* Oct 2010;21:1079-1084.
  44. Ouyang F, Ernst S, Vogtmann T, Goya M, Volkmer M, Schaumann A, Bansch D, Antz M, Kuck KH. Characterization of reentrant circuits in left atrial macroreentrant tachycardia: critical isthmus block can prevent atrial tachycardia recurrence. *Circulation* Apr 23 2002;105:1934-1942.
  45. Ernst S, Ouyang F, Lober F, Antz M, Kuck KH. Catheter-induced linear lesions in the left atrium in patients with atrial fibrillation: an electroanatomic study. *Journal of the American College of Cardiology* Oct 1 2003;42:1271-1282.
  46. Pappone C, Manguso F, Vicedomini G, et al. Prevention of iatrogenic atrial tachycardia after ablation of atrial fibrillation: a prospective randomized study comparing circumferential pulmonary vein ablation with a modified approach. *Circulation* Nov 9 2004;110:3036-3042.
  47. Gerstenfeld EP, Callans DJ, Dixit S, Russo AM, Nayak H, Lin D, Pulliam W, Siddique S, Marchlinski FE. Mechanisms of organized left atrial tachycardias occurring after pulmonary vein isolation. *Circulation* Sep 14 2004;110:1351-1357.
  48. Haissaguerre M, Hocini M, Sanders P, et al. Catheter ablation of long-lasting persistent atrial fibrillation: clinical outcome and mechanisms of subsequent arrhythmias. *Journal of cardiovascular electrophysiology* Nov 2005;16:1138-1147.
  49. Hocini M, Sanders P, Jais P, Hsu LF, Weerasoriya R, Scavee C, Takahashi Y, Rotter M, Raybaud F, Macle L, Clementy J, Haissaguerre M. Prevalence of pulmonary vein disconnection after anatomical ablation for atrial fibrillation: consequences of wide atrial encircling of the pulmonary veins. *European heart journal* Apr 2005;26:696-704.
  50. Rostock T, O'Neill MD, Sanders P, Rotter M, Jais P, Hocini M, Takahashi Y, Sacher F, Jonsson A, Hsu LF, Clementy J, Haissaguerre M. Characterization of conduction recovery across left atrial linear lesions in patients with paroxysmal and persistent atrial fibrillation. *Journal of cardiovascular electrophysiology* Oct 2006;17:1106-1111.
  51. Knecht S, Hocini M, Wright M, et al. Left atrial linear lesions are required for successful treatment of persistent atrial fibrillation. *European heart journal* Oct 2008;29:2359-2366.
  52. Chae S, Oral H, Good E, et al. Atrial tachycardia after circumferential pulmonary vein ablation of atrial fibrillation: mechanistic insights, results of catheter ablation, and risk factors for recurrence. *Journal of the American College of Cardiology* Oct 30 2007;50:1781-1787.
  53. Matsuo S, Wright M, Knecht S, Nault I, Lellouche N, Lim KT, Arantes L, O'Neill MD, Hocini M, Jais P, Haissaguerre M. Peri-mitral atrial flutter in patients with atrial fibrillation ablation. *Heart rhythm : the official journal of the Heart Rhythm Society* Jan 2010;7:2-8.
  54. Yokokawa M, Latchamsetty R, Ghanbari H, et al. Characteristics of atrial tachycardia due to small vs large reentrant circuits after ablation of persistent atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Apr 2013;10:469-476.
  55. Kiser AC, Landers M, Horton R, Hume A, Natale A, Gersak B. The convergent procedure: a multidisciplinary atrial fibrillation treatment. *The heart surgery forum* Oct 2010;13:E317-321.
  56. Lee R, McCarthy PM, Passman RS, Kruse J, Malaisrie SC, McGee EC, Lapin B, Jacobson JT, Goldberger J, Knight BP. Surgical treatment for isolated atrial fibrillation: minimally invasive vs. classic cut and sew maze. *Innovations (Philadelphia, Pa)* Nov 2011;6:373-377.
  57. Mahapatra S, LaPar DJ, Kamath S, Payne J, Bilchick KC, Mangrum JM, Ailawadi G. Initial experience of sequential surgical epicardial-catheter endocardial ablation for persistent and long-standing persistent atrial fibrillation with long-term follow-up. *The Annals of thoracic surgery* Jun 2011;91:1890-1898.

58. Pison L, Dagnes N, Lewalter T, Proclemer A, Marinskis G, Blomstrom-Lundqvist C. Surgical and hybrid atrial fibrillation ablation procedures. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* Jul 2012;14:939-941.
59. La Meir M, Gelsomino S, Lorusso R, Luca F, Pison L, Parise O, Wellens F, Gensini GF, Maessen J. The hybrid approach for the surgical treatment of lone atrial fibrillation: one-year results employing a monopolar radiofrequency source. *Journal of cardiothoracic surgery* 2012;7:71.
60. Bisleri G, Rosati F, Bontempi L, Curnis A, Muneretto C. Hybrid approach for the treatment of long-standing persistent atrial fibrillation: electrophysiological findings and clinical results. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery* Nov 2013;44:919-923.
61. Gehi AK, Mounsey JP, Pursell I, Landers M, Boyce K, Chung EH, Schwartz J, Walker TJ, Guise K, Kiser AC. Hybrid epicardial-endocardial ablation using a pericardioscopic technique for the treatment of atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Jan 2013;10:22-28.
62. La Meir M, Gelsomino S, Luca F, Pison L, Parise O, Colella A, Gensini GF, Crijns H, Wellens F, Maessen JG. Minimally invasive surgical treatment of lone atrial fibrillation: early results of hybrid versus standard minimally invasive approach employing radiofrequency sources. *International journal of cardiology* Aug 20 2013;167:1469-1475.
63. Kurfurst V, Mokracek A, Bulava A, Canadyova J, Hanis J, Pesl L. Two-staged hybrid treatment of persistent atrial fibrillation: short-term single-centre results. *Interactive cardiovascular and thoracic surgery* Apr 2014;18:451-456.
64. Lee HM, Chung SR, Jeong DS. Initial experience with total thorascopic ablation. *The Korean journal of thoracic and cardiovascular surgery* Feb 2014;47:1-5.
65. Pison L, Gelsomino S, Luca F, Parise O, Maessen JG, Crijns HJ, La Meir M. Effectiveness and safety of simultaneous hybrid thorascopic and endocardial catheter ablation of lone atrial fibrillation. *Annals of cardiothoracic surgery* Jan 2014;3:38-44.
66. Gersak B, Zembala MO, Muller D, Folliguet T, Jan M, Kowalski O, Erler S, Bars C, Robic B, Filipiak K, Wimmer-Greinecker G. European experience of the convergent atrial fibrillation procedure: multicenter outcomes in consecutive patients. *The Journal of thoracic and cardiovascular surgery* Apr 2014;147:1411-1416.
67. Kiser AC, Landers MD, Boyce K, Sinkovec M, Pernat A, Gersak B. Simultaneous catheter and epicardial ablations enable a comprehensive atrial fibrillation procedure. *Innovations (Philadelphia, Pa)* Jul 2011;6:243-247.
68. Gersak B, Pernat A, Robic B, Sinkovec M. Low rate of atrial fibrillation recurrence verified by implantable loop recorder monitoring following a convergent epicardial and endocardial ablation of atrial fibrillation. *Journal of cardiovascular electrophysiology* Oct 2012;23:1059-1066.
69. Zembala M, Filipiak K, Kowalski O, Boidol J, Sokal A, Lenarczyk R, Niklewski T, Garbacz M, Nadziakiewicz P, Kalarus Z, Zembala M. Minimally invasive hybrid ablation procedure for the treatment of persistent atrial fibrillation: one year results. *Kardiologia polska* 2012;70:819-828.
70. Muneretto C, Bisleri G, Bontempi L, Curnis A. Durable staged hybrid ablation with thorascopic and percutaneous approach for treatment of long-standing atrial fibrillation: a 30-month assessment with continuous monitoring. *The Journal of thoracic and cardiovascular surgery* Dec 2012;144:1460-1465; discussion 1465.
71. Gilligan DM, Joyner CA, Bundy GM. Multidisciplinary collaboration for the treatment of atrial fibrillation: convergent procedure outcomes from a single center. *J Innov CRM* 2013;2013:1396-1403.
72. Civello KC, Smith CA, Boedefeld W. Combined endocardial and epicardial ablation for symptomatic atrial fibrillation: single center experience in 100+ consecutive patients. *J Innov CRM* 2013;000:1-7.
73. Thosani AJ, Gerczuk P, Liu E, Belden W, Moraca R. Closed chest convergent epicardial-endocardial ablation of non-paroxysmal atrial fibrillation - a case series and literature review. *Arrhythmia & Electrophysiology Review* 2013;2:65-68.
74. Robinson MC, Chiravuri M, McPherson C, Winslow R. Maximizing ablation, limiting invasiveness, and being realistic about atrial fibrillation: the convergent hybrid ablation procedure for advanced AF. *EP Lab Digest* 2013;13.
75. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Journal of the American College of Cardiology* Dec 2 2014;64:e1-e76.
76. Pinho-Gomes AC, Amorim MJ, Oliveira SM, Leite-Moreira AF. Surgical treatment of atrial fibrillation: an updated review. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery* Aug 2014;46:167-178.
77. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. *Heart rhythm : the official journal of the Heart Rhythm Society* Apr 2012;9:632-696 e621.
78. Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. *Jama* Feb 5 2014;311:498-506.
79. Katritsis D, Ioannidis JP, Anagnostopoulos CE, Sarris GE, Giazitzoglou E, Korovesis S, Camm AJ. Identification and catheter ablation of extracardiac and intracardiac components of ligament of Marshall tissue for treatment of paroxysmal atrial fibrillation. *Journal of cardiovascular electrophysiology* Jul 2001;12:750-758.
80. Oral H, Chugh A, Scharf C, Hall B, Cheung P, Veerareddy S, Daneshvar GF, Pelosi F, Jr., Morady F. Pulmonary vein isolation for vagotonic, adrenergic, and random episodes of paroxysmal atrial fibrillation. *Journal of cardiovascular electrophysiology* Apr 2004;15:402-406.
81. Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. *Circulation* Jan 27 2004;109:327-334.
82. Scherlag BJ, Nakagawa H, Jackman WM, Yamanashi WS, Patterson E, Po S, Lazzara R. Electrical stimulation to identify neural elements on the heart: their role in atrial fibrillation. *Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing* Aug 2005;13 Suppl 1:37-42.
83. Lellouche N, Buch E, Celigoj A, Siegeman C, Cesario D, De Diego C, Mahajan A, Boyle NG, Wiener I, Garfinkel A, Shivkumar K. Functional characterization of atrial electrograms in sinus rhythm delineates sites of parasympathetic innervation in patients with paroxysmal atrial fibrillation. *Journal of the American College of Cardiology* Oct 2 2007;50:1324-1331.
84. Pokushalov E, Romanov A, Shugayev P, Artyomenko S, Shirokova N, Turov A, Katritsis DG. Selective ganglionated plexi ablation for paroxysmal atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Sep 2009;6:1257-1264.

85. Katritsis D, Giazitzoglou E, Sougiannis D, Voridis E, Po SS. Complex fractionated atrial electrograms at anatomic sites of ganglionated plexi in atrial fibrillation. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* Mar 2009;11:308-315.
86. Nakagawa H, Scherlag BJ, Patterson E, Ikeda A, Lockwood D, Jackman WM. Pathophysiologic basis of autonomic ganglionated plexus ablation in patients with atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Dec 2009;6:S26-34.
87. Po SS, Nakagawa H, Jackman WM. Localization of left atrial ganglionated plexi in patients with atrial fibrillation. *Journal of cardiovascular electrophysiology* Oct 2009;20:1186-1189.
88. Calo L, Rebecchi M, Sciarra L, De Luca L, Fagagnini A, Zuccaro LM, Pitrone P, Dottori S, Porfirio M, de Ruvo E, Lioy E. Catheter ablation of right atrial ganglionated plexi in patients with vagal paroxysmal atrial fibrillation. *Circulation Arrhythmia and electrophysiology* Feb 2012;5:22-31.
89. Kondo Y, Ueda M, Watanabe M, Ishimura M, Kajiyama T, Hashiguchi N, Kanaeda T, Nakano M, Hiranuma Y, Ishizaka T, Matsumiya G, Kobayashi Y. Identification of left atrial ganglionated plexi by dense epicardial mapping as ablation targets for the treatment of concomitant atrial fibrillation. *Pacing and clinical electrophysiology : PACE* Nov 2013;36:1336-1341.
90. Noheria A, Patel SM, Mirzoyev S, Madhavan M, Friedman PA, Packer DL, Daly RC, Kushwaha SS, Edwards BS, Asirvatham SJ. Decreased postoperative atrial fibrillation following cardiac transplantation: the significance of autonomic denervation. *Pacing and clinical electrophysiology : PACE* Jun 2013;36:741-747.
91. Pokushalov E, Romanov A, Katritsis DG, Artyomenko S, Shirokova N, Karasov A, Mittal S, Steinberg JS. Ganglionated plexus ablation vs linear ablation in patients undergoing pulmonary vein isolation for persistent/long-standing persistent atrial fibrillation: a randomized comparison. *Heart rhythm : the official journal of the Heart Rhythm Society* Sep 2013;10:1280-1286.
92. Katritsis DG, Pokushalov E, Romanov A, Giazitzoglou E, Siontis GC, Po SS, Camm AJ, Ioannidis JP. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. *Journal of the American College of Cardiology* Dec 17 2013;62:2318-2325.
93. Al-Atassi T, Toeg H, Malas T, Lam BK. Mapping and ablation of autonomic ganglia in prevention of postoperative atrial fibrillation in coronary surgery: MAAPPAFS atrial fibrillation randomized controlled pilot study. *The Canadian journal of cardiology* Oct 2014;30:1202-1207.
94. Kurotobi T, Shimada Y, Kino N, Ito K, Tonomura D, Yano K, Tanaka C, Yoshida M, Tsuchida T, Fukumoto H. Features of intrinsic ganglionated plexi in both atria after extensive pulmonary isolation and their clinical significance after catheter ablation in patients with atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Mar 2015;12:470-476.
95. Stavrakis S, Humphrey MB, Scherlag BJ, Hu Y, Jackman WM, Nakagawa H, Lockwood D, Lazzara R, Po SS. Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation. *Journal of the American College of Cardiology* Mar 10 2015;65:867-875.
96. Yalcin MU, Gurses KM, Kocyigit D, et al. Cardiac autoantibody levels predict recurrence following cryoballoon-based pulmonary vein isolation in paroxysmal atrial fibrillation patients. *Journal of cardiovascular electrophysiology* Mar 19 2015.
97. Jongnarangsin K, Chugh A, Good E, et al. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. *Journal of cardiovascular electrophysiology* Jul 2008;19:668-672.
98. Tang RB, Dong JZ, Liu XP, Long DY, Yu RH, Kalifa J, Ma CS. Metabolic syndrome and risk of recurrence of atrial fibrillation after catheter ablation. *Circulation journal : official journal of the Japanese Circulation Society* Mar 2009;73:438-443.
99. Bhargava M, Di Biase L, Mohanty P, et al. Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: results from a multicenter study. *Heart rhythm : the official journal of the Heart Rhythm Society* Oct 2009;6:1403-1412.
100. Jongnarangsin K, Suwanagool A, Chugh A, Crawford T, Good E, Pelosi F, Jr., Bogun F, Oral H, Morady F. Effect of catheter ablation on progression of paroxysmal atrial fibrillation. *Journal of cardiovascular electrophysiology* Jan 2012;23:9-14.
101. Mohanty S, Mohanty P, Di Biase L, et al. Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation. *Journal of the American College of Cardiology* Apr 3 2012;59:1295-1301.
102. Chao TF, Tsao HM, Lin YJ, et al. Clinical outcome of catheter ablation in patients with nonparoxysmal atrial fibrillation: results of 3-year follow-up. *Circulation Arrhythmia and electrophysiology* Jun 1 2012;5:514-520.
103. Chao TF, Ambrose K, Tsao HM, et al. Relationship between the CHADS(2) score and risk of very late recurrences after catheter ablation of paroxysmal atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Aug 2012;9:1185-1191.
104. Fein AS, Shvilkin A, Shah D, Haffajee CI, Das S, Kumar K, Kramer DB, Zimetbaum PJ, Buxton AE, Josephson ME, Anter E. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. *Journal of the American College of Cardiology* Jul 23 2013;62:300-305.
105. Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. *Journal of the American College of Cardiology* Dec 2 2014;64:2222-2231.
106. Husser D, Adams V, Piorkowski C, Hindricks G, Bollmann A. Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation. *Journal of the American College of Cardiology* Feb 23 2010;55:747-753.
107. Shoemaker MB, Bollmann A, Lubitz SA, et al. Common Genetic Variants and Response to Atrial Fibrillation Ablation. *Circulation Arrhythmia and electrophysiology* Feb 14 2015.
108. Stiles MK, John B, Wong CX, Kuklik P, Brooks AG, Lau DH, Dimitri H, Roberts-Thomson KC, Wilson L, De Sciscio P, Young GD, Sanders P. Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the "second factor". *Journal of the American College of Cardiology* Apr 7 2009;53:1182-1191.
109. Inoue K, Kurotobi T, Kimura R, Toyoshima Y, Itoh N, Masuda M, Higuchi Y, Date M, Koyama Y, Okamura A, Iwakura K, Fujii K. Trigger-based mechanism of the persistence of atrial fibrillation and its impact on the efficacy of catheter ablation. *Circulation Arrhythmia and electrophysiology* Apr 2012;5:295-301.
110. Kiaii B, Fox S, Chase L, et al. Postoperative atrial fibrillation is not pulmonary vein dependent: Results from a randomized trial. *Heart rhythm : the official journal of the Heart Rhythm Society* Apr 2015;12:699-705.
111. Sanders P, Berenfeld O, Hocini M, et al. Spectral analysis identifies sites of high-frequency activity maintaining atrial fibrillation in humans. *Circulation* Aug 9 2005;112:789-797.
112. Jarman JW, Wong T, Kojodjojo P, Spohr H, Davies JE, Roughton M, Francis DP, Kanagaratnam P, Markides V, Davies DW, Peters NS. Spatiotemporal behavior of high dominant frequency during paroxysmal and persistent atrial fibrillation in the human left atrium. *Circulation Arrhythmia and electrophysiology* Aug 1 2012;5:650-658.
113. Atria F, Almendral J, Ormaetxe JM, et al. Comparison of Radiofrequency Catheter Ablation of Drivers and Circumferential Pulmonary Vein Isolation in Atrial Fibrillation: A Noninferiority Randomized Multicenter RADAR-AF Trial. *Journal of the American College of Cardiology* Dec 16 2014;64:2455-2467.
114. Oral H, Chugh A, Good E, et al. Randomized evaluation of right atrial ablation

- after left atrial ablation of complex fractionated atrial electrograms for long-lasting persistent atrial fibrillation. *Circulation Arrhythmia and electrophysiology* Apr 2008;1:6-13.
115. Hocini M, Nault I, Wright M, et al. Disparate evolution of right and left atrial rate during ablation of long-lasting persistent atrial fibrillation. *Journal of the American College of Cardiology* Mar 9 2010;55:1007-1016.
  116. Garrey WE. The nature of fibrillary contraction of the heart: its relation to tissue mass and form. *The American journal of physiology* 1914;33:397-414.
  117. Moe GK, Rheinboldt WC, Abildskov JA. A Computer Model of Atrial Fibrillation. *American heart journal* Feb 1964;67:200-220.
  118. Byrd GD, Prasad SM, Ripplinger CM, Cassilly TR, Schuessler RB, Boineau JP, Damiano RJ, Jr. Importance of geometry and refractory period in sustaining atrial fibrillation: testing the critical mass hypothesis. *Circulation* Aug 30 2005;112:17-13.
  119. Asirvatham SJ, Jiao Z. What causes atrial fibrillation and why do we fail with ablation?: insights from metabolic syndrome. *Journal of the American College of Cardiology* Apr 3 2012;59:1302-1303.
  120. Kottkamp H, Bender R, Berg J. Catheter ablation of atrial fibrillation: how to modify the substrate? *Journal of the American College of Cardiology* Jan 20 2015;65:196-206.
  121. Jais P, Hocini M, Sanders P, Hsu LF, Takahashi Y, Rotter M, Rostock T, Sacher F, Clementy J, Haissaguerre M. Long-term evaluation of atrial fibrillation ablation guided by noninducibility. *Heart rhythm : the official journal of the Heart Rhythm Society* Feb 2006;3:140-145.
  122. Oral H, Chugh A, Good E, et al. A tailored approach to catheter ablation of paroxysmal atrial fibrillation. *Circulation* Apr 18 2006;113:1824-1831.
  123. Cuculich PS, Wang Y, Lindsay BD, Faddis MN, Schuessler RB, Damiano RJ, Jr., Li L, Rudy Y. Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns. *Circulation* Oct 5 2010;122:1364-1372.
  124. Yoshida K, Rabbani AB, Oral H, Bach D, Morady F, Chugh A. Left atrial volume and dominant frequency of atrial fibrillation in patients undergoing catheter ablation of persistent atrial fibrillation. *Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing* Nov 2011;32:155-161.
  125. Rostock T, Salukhe TV, Steven D, et al. Long-term single- and multiple-procedure outcome and predictors of success after catheter ablation for persistent atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Sep 2011;8:1391-1397.
  126. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ, Miller JM. Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. *Journal of the American College of Cardiology* Aug 14 2012;60:628-636.
  127. Rostock T, Salukhe TV, Hoffmann BA, Steven D, Berner I, Mullerleile K, Theis C, Bock K, Servatius H, Sultan A, Willems S. Prognostic role of subsequent atrial tachycardias occurring during ablation of persistent atrial fibrillation: a prospective randomized trial. *Circulation Arrhythmia and electrophysiology* Dec 2013;6:1059-1065.
  128. Haissaguerre M, Hocini M, Denis A, et al. Driver domains in persistent atrial fibrillation. *Circulation* Aug 12 2014;130:530-538.
  129. Scherr D, Khairy P, Miyazaki S, et al. Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint. *Circulation Arrhythmia and electrophysiology* Feb 2015;8:18-24.
  130. Chugh A. Atrial tachycardia after ablation of persistent atrial fibrillation: is it us or them? *Circulation Arrhythmia and electrophysiology* Dec 2013;6:1047-1049.
  131. Chugh A. Catheter ablation of persistent atrial fibrillation: how much is enough? *Circulation Arrhythmia and electrophysiology* Feb 2015;8:2-4.
  132. Nathan H, Gloobe H. Myocardial atrio-venous junctions and extensions (sleeves) over the pulmonary and caval veins. Anatomical observations in various mammals. *Thorax* May 1970;25:317-324.
  133. DeSimone CV, Noheria A, Lachman N, Edwards WD, Gami AS, Maleszewski JJ, Friedman PA, Munger TM, Hammill SC, Packer DL, Asirvatham SJ. Myocardium of the superior vena cava, coronary sinus, vein of Marshall, and the pulmonary vein ostia: gross anatomic studies in 620 hearts. *Journal of cardiovascular electrophysiology* Dec 2012;23:1304-1309.
  134. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Metayer P, Clementy J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *The New England journal of medicine* Sep 3 1998;339:659-666.
  135. Chen SA, Hsieh MH, Tai CT, Tsai CF, Prakash VS, Yu WC, Hsu TL, Ding YA, Chang MS. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. *Circulation* Nov 2 1999;100:1879-1886.
  136. Robbins IM, Colvin EV, Doyle TP, Kemp WE, Loyd JE, McMahon WS, Kay GN. Pulmonary vein stenosis after catheter ablation of atrial fibrillation. *Circulation* Oct 27 1998;98:1769-1775.
  137. Gerstenfeld EP, Guerra P, Sparks PB, Hattori K, Lesh MD. Clinical outcome after radiofrequency catheter ablation of focal atrial fibrillation triggers. *Journal of cardiovascular electrophysiology* Aug 2001;12:900-908.
  138. Yu WC, Hsu TL, Tai CT, Tsai CF, Hsieh MH, Lin WS, Lin YK, Tsao HM, Ding YA, Chang MS, Chen SA. Acquired pulmonary vein stenosis after radiofrequency catheter ablation of paroxysmal atrial fibrillation. *Journal of cardiovascular electrophysiology* Aug 2001;12:887-892.
  139. Haissaguerre M, Shah DC, Jais P, Hocini M, Yamane T, Deisenhofer I, Chauvin M, Garrigue S, Clementy J. Electrophysiological breakthroughs from the left atrium to the pulmonary veins. *Circulation* Nov 14 2000;102:2463-2465.
  140. Oral H, Knight BP, Ozaydin M, Chugh A, Lai SW, Scharf C, Hassan S, Greenstein R, Han JD, Pelosi F, Jr., Strickberger SA, Morady F. Segmental ostial ablation to isolate the pulmonary veins during atrial fibrillation: feasibility and mechanistic insights. *Circulation* Sep 3 2002;106:1256-1262.
  141. Pappone C, Rosanio S, Oreto G, Tocchi M, Gugliotta F, Vicedomini G, Salvati A, Dicandia C, Mazzone P, Santinelli V, Gulletta S, Chierchia S. Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. *Circulation* Nov 21 2000;102:2619-2628.
  142. Pappone C, Oreto G, Rosanio S, et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. *Circulation* Nov 20 2001;104:2539-2544.
  143. Kanagaratnam L, Tomassoni G, Schweikert R, Pavia S, Bash D, Beheiry S, Lesh M, Niebauer M, Saliba W, Chung M, Tchou P, Natale A. Empirical pulmonary vein isolation in patients with chronic atrial fibrillation using a three-dimensional nonfluoroscopic mapping system: long-term follow-up. *Pacing and clinical electrophysiology : PACE* Dec 2001;24:1774-1779.
  144. Oral H, Ozaydin M, Tada H, Chugh A, Scharf C, Hassan S, Lai S, Greenstein R, Pelosi F, Jr., Knight BP, Strickberger SA, Morady F. Mechanistic significance of intermittent pulmonary vein tachycardia in patients with atrial fibrillation. *Journal of cardiovascular electrophysiology* Jul 2002;13:645-650.
  145. Willems S, Weiss C, Risius T, Rostock T, Hoffmann M, Ventura R, Meinertz T. Dissociated activity and pulmonary vein fibrillation following functional disconnection: impact for the arrhythmogenesis of focal atrial fibrillation. *Pacing and clinical electrophysiology : PACE* Jun 2003;26:1363-1370.
  146. Ouyang F, Bansch D, Ernst S, Schaumann A, Hachiya H, Chen M, Chun J, Falk P, Khanedani A, Antz M, Kuck KH. Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double-Lasso technique in paroxysmal atrial fibrillation. *Circulation* Oct 12 2004;110:2090-2096.
  147. Marchlinski FE, Callans D, Dixit S, Gerstenfeld EP, Rho R, Ren JF, Zado E.

- Efficacy and safety of targeted focal ablation versus PV isolation assisted by magnetic electroanatomic mapping. *Journal of cardiovascular electrophysiology* Apr 2003;14:358-365.
148. Nakashima H, Kumagai K, Noguchi H, Tojo H, Yasuda T, Saku K. Evaluation of the recurrence of atrial fibrillation after pulmonary venous ablation. *Journal of cardiology* Sep 2002;40:87-94.
  149. Takahashi A, Iesaka Y, Takahashi Y, Takahashi R, Kobayashi K, Takagi K, Kuboyama O, Nishimori T, Takei H, Amemiya H, Fujiwara H, Hiraoka M. Electrical connections between pulmonary veins: implication for ostial ablation of pulmonary veins in patients with paroxysmal atrial fibrillation. *Circulation* Jun 25 2002;105:2998-3003.
  150. Cabrera JA, Ho SY, Climent V, Fuertes B, Murillo M, Sanchez-Quintana D. Morphological evidence of muscular connections between contiguous pulmonary venous orifices: relevance of the interpulmonary isthmus for catheter ablation in atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Aug 2009;6:1192-1198.
  151. Shah D, Haissaguerre M, Jais P, Hocini M. Nonpulmonary vein foci: do they exist? *Pacing and clinical electrophysiology : PACE* Jul 2003;26:1631-1635.
  152. Macedo PG, Kapa S, Mears JA, Fratianni A, Asirvatham SJ. Correlative anatomy for the electrophysiologist: ablation for atrial fibrillation. Part I: pulmonary vein ostia, superior vena cava, vein of Marshall. *Journal of cardiovascular electrophysiology* Jun 1 2010;21:721-730.
  153. Oral H, Scharf C, Chugh A, Hall B, Cheung P, Good E, Veerareddy S, Pelosi F, Jr, Morady F. Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation. *Circulation* Nov 11 2003;108:2355-2360.
  154. Karch MR, Zrenner B, Deisenhofer I, Schreieck J, Ndrepepa G, Dong J, Lamprecht K, Barthel P, Luciani E, Schomig A, Schmitt C. Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. *Circulation* Jun 7 2005;111:2875-2880.
  155. Liu X, Dong J, Mavrakis HE, et al. Achievement of pulmonary vein isolation in patients undergoing circumferential pulmonary vein ablation: a randomized comparison between two different isolation approaches. *Journal of cardiovascular electrophysiology* Dec 2006;17:1263-1270.
  156. Arentz T, Weber R, Burkle G, Herrera C, Blum T, Stockinger J, Minners J, Neumann FJ, Kalusche D. Small or large isolation areas around the pulmonary veins for the treatment of atrial fibrillation? Results from a prospective randomized study. *Circulation* Jun 19 2007;115:3057-3063.
  157. Nilsson B, Chen X, Pehrson S, Kober L, Hilden J, Svendsen JH. Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: a randomized trial of the ostial versus the extraostial ablation strategy. *American heart journal* Sep 2006;152:537 e531-538.
  158. Lemola K, Hall B, Cheung P, Good E, Han J, Tamirisa K, Chugh A, Bogun F, Pelosi F, Jr, Morady F, Oral H. Mechanisms of recurrent atrial fibrillation after pulmonary vein isolation by segmental ostial ablation. *Heart rhythm : the official journal of the Heart Rhythm Society* Jul 2004;1:197-202.
  159. Tamborero D, Mont L, Berruezo A, Guasch E, Rios J, Nadal M, Matiello M, Andreu D, Sitges M, Brugada J. Circumferential pulmonary vein ablation: does use of a circular mapping catheter improve results? A prospective randomized study. *Heart rhythm : the official journal of the Heart Rhythm Society* May 2010;7:612-618.
  160. Zhang B, Zhen Y, Tao A, Zhang G. Efficacy of selective arrhythmogenic pulmonary veins isolation versus empirical all pulmonary veins isolation for atrial fibrillation: a meta-analysis of randomized and observational studies. *Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing* Apr 2014;39:233-240.
  161. Lazar S, Dixit S, Marchlinski FE, Callans DJ, Gerstenfeld EP. Presence of left-to-right atrial frequency gradient in paroxysmal but not persistent atrial fibrillation in humans. *Circulation* Nov 16 2004;110:3181-3186.
  162. Lo LW, Tai CT, Lin YJ, Chang SL, Wongcharoen W, Hsieh MH, Tuan TC, Udyavar AR, Hu YF, Chen YJ, Tsao HM, Chen SA. Mechanisms of recurrent atrial fibrillation: comparisons between segmental ostial versus circumferential pulmonary vein isolation. *Journal of cardiovascular electrophysiology* Aug 2007;18:803-807.
  163. Yamada T, Murakami Y, Okada T, et al. Non-pulmonary vein epicardial foci of atrial fibrillation identified in the left atrium after pulmonary vein isolation. *Pacing and clinical electrophysiology : PACE* Nov 2007;30:1323-1330.
  164. Lin YJ, Chang SL, Lo LW, et al. A prospective, randomized comparison of modified pulmonary vein isolation versus conventional pulmonary vein isolation in patients with paroxysmal atrial fibrillation. *Journal of cardiovascular electrophysiology* Nov 2012;23:1155-1162.
  165. Suenari K, Lin YJ, Chang SL, et al. Relationship between arrhythmogenic pulmonary veins and the surrounding atrial substrate in patients with paroxysmal atrial fibrillation. *Journal of cardiovascular electrophysiology* Apr 2011;22:405-410.
  166. Jarman JW, Wong T, Kojodjojo P, Spohr H, Davies JE, Roughton M, Francis DP, Kanagaratnam P, O'Neill MD, Markides V, Davies DW, Peters NS. Organizational index mapping to identify focal sources during persistent atrial fibrillation. *Journal of cardiovascular electrophysiology* Apr 2014;25:355-363.
  167. Deneke T, Khargi K, Muller KM, Lemke B, Mugge A, Laczkovics A, Becker AE, Grewe PH. Histopathology of intraoperatively induced linear radiofrequency ablation lesions in patients with chronic atrial fibrillation. *European heart journal* Sep 2005;26:1797-1803.
  168. Puodziukynas A, Kazakevicius T, Vaitkevicius R, et al. Radiofrequency catheter ablation of pulmonary vein roots results in axonal degeneration of distal epicardial nerves. *Autonomic neuroscience : basic & clinical* Apr 3 2012;167:61-65.
  169. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. *Journal of the American College of Cardiology* Dec 5 2006;48:2340-2347.
  170. Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, Turco P, Pascotto P, Fazzari M, Vitale DF. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). *European heart journal* Jan 2006;27:216-221.
  171. Forleo GB, Mantica M, De Luca L, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. *Journal of cardiovascular electrophysiology* Jan 2009;20:22-28.
  172. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. *Jama* Jan 27 2010;303:333-340.
  173. Packer DL, Kowal RC, Wheelan KR, Irwin JM, Champagne J, Guerra PG, Dubuc M, Reddy V, Nelson L, Holcomb RG, Lehmann JW, Ruskin JN. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. *Journal of the American College of Cardiology* Apr 23 2013;61:1713-1723.
  174. Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, Sterns LD, Beresh H, Healey JS, Natale A, Investigators R-. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. *Jama* Feb 19 2014;311:692-700.
  175. Ghanbari H, Baser K, Jongnarangsin K, et al. Mortality and cerebrovascular events after radiofrequency catheter ablation of atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Sep 2014;11:1503-1511.
  176. Takigawa M, Takahashi A, Kuwahara T, et al. Long-term follow-up after

- catheter ablation of paroxysmal atrial fibrillation: the incidence of recurrence and progression of atrial fibrillation. *Circulation Arrhythmia and electrophysiology* Apr 2014;7:267-273.
177. Ouyang F, Tilz R, Chun J, Schmidt B, Wissner E, Zerm T, Neven K, Kokturk B, Konstantinidou M, Metzner A, Fuernkranz A, Kuck KH. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. *Circulation* Dec 7 2010;122:2368-2377.
  178. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, Boone J, Sheldon R, Dorian P, Newman D. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. *American heart journal* Mar 2005;149:489-496.
  179. Tsai CF, Tai CT, Hsieh MH, Lin WS, Yu WC, Ueng KC, Ding YA, Chang MS, Chen SA. Initiation of atrial fibrillation by ectopic beats originating from the superior vena cava: electrophysiological characteristics and results of radiofrequency ablation. *Circulation* Jul 4 2000;102:67-74.
  180. Arruda M, Mlcochova H, Prasad SK, et al. Electrical isolation of the superior vena cava: an adjunctive strategy to pulmonary vein antrum isolation improving the outcome of AF ablation. *Journal of cardiovascular electrophysiology* Dec 2007;18:1261-1266.
  181. Oral H, Ozaydin M, Chugh A, Scharf C, Tada H, Hall B, Cheung P, Pelosi F, Knight BP, Morady F. Role of the coronary sinus in maintenance of atrial fibrillation. *Journal of cardiovascular electrophysiology* Dec 2003;14:1329-1336.
  182. Cabrera JA, Ho SY, Climent V, Sanchez-Quintana D. The architecture of the left lateral atrial wall: a particular anatomic region with implications for ablation of atrial fibrillation. *European heart journal* Feb 2008;29:356-362.
  183. Hwang C, Wu TJ, Doshi RN, Peter CT, Chen PS. Vein of marshall cannulation for the analysis of electrical activity in patients with focal atrial fibrillation. *Circulation* Apr 4 2000;101:1503-1505.
  184. Chugh A, Wimmer A, Morady F. Elimination of left superior pulmonary vein ostial potentials during radiofrequency ablation at the mitral isthmus. *Heart rhythm : the official journal of the Heart Rhythm Society* Jan 2007;4:85-87.
  185. Oral H, Knight BP, Ozaydin M, Tada H, Chugh A, Hassan S, Scharf C, Lai SW, Greenstein R, Pelosi F, Jr., Strickberger SA, Morady F. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. *Journal of the American College of Cardiology* Jul 3 2002;40:100-104.
  186. Lellouche N, Jais P, Nault I, et al. Early recurrences after atrial fibrillation ablation: prognostic value and effect of early reablation. *Journal of cardiovascular electrophysiology* Jun 2008;19:599-605.
  187. Richter B, Gwechenberger M, Socas A, Marx M, Gossinger HD. Frequency of recurrence of atrial fibrillation within 48 hours after ablation and its impact on long-term outcome. *The American journal of cardiology* Mar 15 2008;101:843-847.
  188. Arya A, Hindricks G, Sommer P, Huo Y, Bollmann A, Gaspar T, Bode K, Husser D, Kottkamp H, Piorkowski C. Long-term results and the predictors of outcome of catheter ablation of atrial fibrillation using steerable sheath catheter navigation after single procedure in 674 patients. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* Feb 2010;12:173-180.
  189. Andrade JG, Macle L, Khairy P, et al. Incidence and significance of early recurrences associated with different ablation strategies for AF: a STAR-AF substudy. *Journal of cardiovascular electrophysiology* Dec 2012;23:1295-1301.
  190. Andrade JG, Khairy P, Macle L, Packer DL, Lehmann JW, Holcomb RG, Ruskin JN, Dubuc M. Incidence and significance of early recurrences of atrial fibrillation after cryoballoon ablation: insights from the multicenter Sustained Treatment of Paroxysmal Atrial Fibrillation (STOP AF) Trial. *Circulation Arrhythmia and electrophysiology* Feb 2014;7:69-75.
  191. Baman TS, Gupta SK, Billakanty SR, et al. Time to cardioversion of recurrent atrial arrhythmias after catheter ablation of atrial fibrillation and long-term clinical outcome. *Journal of cardiovascular electrophysiology* Dec 2009;20:1321-1325.
  192. Leong-Sit P, Roux JF, Zado E, et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. *Circulation Arrhythmia and electrophysiology* Feb 2011;4:11-14.
  193. Roux JF, Zado E, Callans DJ, et al. Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study). *Circulation* Sep 22 2009;120:1036-1040.
  194. Hayashi M, Miyauchi Y, Iwasaki YK, Yodogawa K, Tsuboi I, Uetake S, Hayashi H, Takahashi K, Shimizu W. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* Aug 2014;16:1160-1167.
  195. Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen JB, Svendsen JH. Recurrence of arrhythmia following short-term oral AMIOdarone after CATHeter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). *European heart journal* Dec 14 2014;35:3356-3364.
  196. Pokushalov E, Romanov A, De Melis M, Artyomenko S, Baranova V, Losik D, Bairamova S, Karaskov A, Mittal S, Steinberg JS. Progression of atrial fibrillation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation: a randomized comparison of drug therapy versus reablation. *Circulation Arrhythmia and electrophysiology* Aug 2013;6:754-760.
  197. Gerstenfeld EP, Callans DJ, Dixit S, Zado E, Marchlinski FE. Incidence and location of focal atrial fibrillation triggers in patients undergoing repeat pulmonary vein isolation: implications for ablation strategies. *Journal of cardiovascular electrophysiology* Jul 2003;14:685-690.
  198. Nanthakumar K, Plumb VJ, Epstein AE, Veenhuyzen GD, Link D, Kay GN. Resumption of electrical conduction in previously isolated pulmonary veins: rationale for a different strategy? *Circulation* Mar 16 2004;109:1226-1229.
  199. Verma A, Kilicaslan F, Pisano E, et al. Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction. *Circulation* Aug 2 2005;112:627-635.
  200. Miyazaki S, Kuwahara T, Kobori A, Takahashi Y, Takei A, Sato A, Isobe M, Takahashi A. Long-term clinical outcome of extensive pulmonary vein isolation-based catheter ablation therapy in patients with paroxysmal and persistent atrial fibrillation. *Heart* Apr 2011;97:668-673.
  201. Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS, Sullivan T, Roberts-Thomson KC, Sanders P. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. *Journal of the American Heart Association* Apr 2013;2:e004549.
  202. McGann CJ, Kholmovski EG, Oakes RS, et al. New magnetic resonance imaging-based method for defining the extent of left atrial wall injury after the ablation of atrial fibrillation. *Journal of the American College of Cardiology* Oct 7 2008;52:1263-1271.
  203. Peters DC, Wylie JV, Hauser TH, Nezafat R, Han Y, Woo JJ, Taclas J, Kissinger KV, Goddu B, Josephson ME, Manning WJ. Recurrence of atrial fibrillation correlates with the extent of post-procedural late gadolinium enhancement: a pilot study. *JACC Cardiovascular imaging* Mar 2009;2:308-316.
  204. Badger TJ, Daccarett M, Akoum NW, et al. Evaluation of left atrial lesions after initial and repeat atrial fibrillation ablation: lessons learned from delayed-enhancement MRI in repeat ablation procedures. *Circulation Arrhythmia and electrophysiology* Jun 2010;3:249-259.
  205. Arujuna A, Karim R, Caulfield D, Knowles B, Rhode K, Schaeffter T, Kato B, Rinaldi CA, Cooklin M, Razavi R, O'Neill MD, Gill J. Acute pulmonary vein isolation is achieved by a combination of reversible and irreversible atrial injury after catheter ablation: evidence from magnetic resonance imaging. *Circulation Arrhythmia and electrophysiology* Aug 1 2012;5:691-700.
  206. Schmitt C, Ndrepepa G, Weber S, Schmieder S, Weyerbrock S, Schneider M,

- Karch MR, Deisenhofer I, Schreieck J, Zrenner B, Schomig A. Batrial multisite mapping of atrial premature complexes triggering onset of atrial fibrillation. *The American journal of cardiology* Jun 15 2002;89:1381-1387.
207. Lin WS, Tai CT, Hsieh MH, Tsai CF, Lin YK, Tsao HM, Huang JL, Yu WC, Yang SP, Ding YA, Chang MS, Chen SA. Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy. *Circulation* Jul 1 2003;107:3176-3183.
208. Valles E, Fan R, Roux JF, et al. Localization of atrial fibrillation triggers in patients undergoing pulmonary vein isolation: importance of the carina region. *Journal of the American College of Cardiology* Oct 21 2008;52:1413-1420.
209. Kurotobi T, Iwakura K, Inoue K, Kimura R, Okamura A, Koyama Y, Tosyoshima Y, Ito N, Fujii K. Multiple arrhythmogenic foci associated with the development of perpetuation of atrial fibrillation. *Circulation Arrhythmia and electrophysiology* Feb 2010;3:39-45.
210. Di Biase L, Burkhardt JD, Mohanty P, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. *Circulation* Jul 13 2010;122:109-118.
211. Corrado A, Bonso A, Madalosso M, Rossillo A, Themistoclakis S, Di Biase L, Natale A, Raviele A. Impact of systematic isolation of superior vena cava in addition to pulmonary vein antrum isolation on the outcome of paroxysmal, persistent, and permanent atrial fibrillation ablation: results from a randomized study. *Journal of cardiovascular electrophysiology* Jan 2010;21:1-5.
212. Da Costa A, Levallois M, Romeyer-Bouchard C, Bisch L, Gate-Martinet A, Isaz K. Remote-controlled magnetic pulmonary vein isolation combined with superior vena cava isolation for paroxysmal atrial fibrillation: A prospective randomized study. *Archives of cardiovascular diseases* Mar 2015;108:163-171.
213. Wang XH, Liu X, Sun YM, Shi HF, Zhou L, Gu JN. Pulmonary vein isolation combined with superior vena cava isolation for atrial fibrillation ablation: a prospective randomized study. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* May 2008;10:600-605.
214. Deisenhofer I, Estner H, Reents T, Fichtner S, Bauer A, Wu J, Kolb C, Zrenner B, Schmitt C, Hessling G. Does electrogram guided substrate ablation add to the success of pulmonary vein isolation in patients with paroxysmal atrial fibrillation? A prospective, randomized study. *Journal of cardiovascular electrophysiology* May 2009;20:514-521.
215. Di Biase L, Elayi CS, Fahmy TS, et al. Atrial fibrillation ablation strategies for paroxysmal patients: randomized comparison between different techniques. *Circulation Arrhythmia and electrophysiology* Apr 2009;2:113-119.
216. Sawhney N, Anousheh R, Chen W, Feld GK. Circumferential pulmonary vein ablation with additional linear ablation results in an increased incidence of left atrial flutter compared with segmental pulmonary vein isolation as an initial approach to ablation of paroxysmal atrial fibrillation. *Circulation Arrhythmia and electrophysiology* Jun 2010;3:243-248.
217. Hayward RM, Upadhyay GA, Mela T, Ellinor PT, Barrett CD, Heist EK, Verma A, Choudhry NK, Singh JP. Pulmonary vein isolation with complex fractionated atrial electrogram ablation for paroxysmal and nonparoxysmal atrial fibrillation: A meta-analysis. *Heart rhythm : the official journal of the Heart Rhythm Society* Jul 2011;8:994-1000.
218. Mun HS, Joung B, Shim J, Hwang HJ, Kim JY, Lee MH, Pak HN. Does additional linear ablation after circumferential pulmonary vein isolation improve clinical outcome in patients with paroxysmal atrial fibrillation? Prospective randomised study. *Heart* Mar 2012;98:480-484.
219. Wu SH, Jiang WF, Gu J, Zhao L, Wang YL, Liu YG, Zhou L, Gu JN, Xu K, Liu X. Benefits and risks of additional ablation of complex fractionated atrial electrograms for patients with atrial fibrillation: a systematic review and meta-analysis. *International journal of cardiology* Oct 25 2013;169:35-43.
220. Arbelo E, Guiu E, Ramos P, Bisbal F, Borrás R, Andreu D, Tolosana JM, Berrueto A, Brugada J, Mont L. Benefit of left atrial roof linear ablation in paroxysmal atrial fibrillation: a prospective, randomized study. *Journal of the American Heart Association* Oct 2014;3:e000877.
221. Kim TH, Park J, Park JK, Uhm JS, Joung B, Hwang C, Lee MH, Pak HN. Linear ablation in addition to circumferential pulmonary vein isolation (Dallas lesion set) does not improve clinical outcome in patients with paroxysmal atrial fibrillation: a prospective randomized study. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* Oct 21 2014.
222. Nuhlich JM, Steven D, Berner I, Rostock T, Hoffmann B, Servatius H, Sultan A, Luker J, Treszl A, Wegscheider K, Willems S. Impact of biatrial defragmentation in patients with paroxysmal atrial fibrillation: results from a randomized prospective study. *Heart rhythm : the official journal of the Heart Rhythm Society* Sep 2014;11:1536-1542.
223. Fichtner S, Sparr K, Reents T, Ammar S, Semmler V, Dillier R, Buiatti A, Kathan S, Hessling G, Deisenhofer I. Recurrence of paroxysmal atrial fibrillation after pulmonary vein isolation: is repeat pulmonary vein isolation enough? A prospective, randomized trial. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* Feb 18 2015.
224. Chugh A, Oral H, Lemola K, Hall B, Cheung P, Good E, Tamirisa K, Han J, Bogun F, Pelosi F, Jr., Morady F. Prevalence, mechanisms, and clinical significance of macroreentrant atrial tachycardia during and following left atrial ablation for atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* May 2005;2:464-471.
225. Oral H, Knight BP, Tada H, Ozaydin M, Chugh A, Hassan S, Scharf C, Lai SW, Greenstein R, Pelosi F, Jr., Strickberger SA, Morady F. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. *Circulation* Mar 5 2002;105:1077-1081.
226. Elayi CS, Verma A, Di Biase L, et al. Ablation for longstanding permanent atrial fibrillation: results from a randomized study comparing three different strategies. *Heart rhythm : the official journal of the Heart Rhythm Society* Dec 2008;5:1658-1664.
227. Tilz RR, Chun KR, Schmidt B, et al. Catheter ablation of long-standing persistent atrial fibrillation: a lesson from circumferential pulmonary vein isolation. *Journal of cardiovascular electrophysiology* Oct 2010;21:1085-1093.
228. Parkash R, Tang AS, Sapp JL, Wells G. Approach to the catheter ablation technique of paroxysmal and persistent atrial fibrillation: a meta-analysis of the randomized controlled trials. *Journal of cardiovascular electrophysiology* Jul 2011;22:729-738.
229. Willems S, Klemm H, Rostock T, Brandstrup B, Ventura R, Steven D, Risius T, Lutomsky B, Meinertz T. Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison. *European heart journal* Dec 2006;27:2871-2878.
230. Akoum N, Wilber D, Hindricks G, et al. MRI Assessment of Ablation-Induced Scarring in Atrial Fibrillation: Analysis from the DECAAF Study. *Journal of cardiovascular electrophysiology* Feb 27 2015.
231. Chang HY, Lo LW, Lin YJ, et al. Long-term outcome of catheter ablation in patients with atrial fibrillation originating from nonpulmonary vein ectopy. *Journal of cardiovascular electrophysiology* Mar 2013;24:250-258.
232. Yokokawa M, Chugh A, Ulfarsson M, Takaki H, Han L, Yoshida K, Sugimachi M, Morady F, Oral H. Effect of linear ablation on spectral components of atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Dec 2010;7:1732-1737.

233. Razavi M, Zhang S, Delapasse S, Yang D, Ai T, Kar B, Younis G, Rasekh A, Cheng J. The effects of pulmonary vein isolation on the dominant frequency and organization of coronary sinus electrical activity during permanent atrial fibrillation. *Pacing and clinical electrophysiology : PACE* Nov 2006;29:1201-1208.
234. Verma A, Mantovan R, Macle L, De Martino G, Chen J, Morillo CA, Novak P, Calzolari V, Guerra PG, Nair G, Torrecilla EG, Khaykin Y. Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial. *European heart journal* Jun 2010;31:1344-1356.
235. Wynn GJ, Das M, Bonnett LJ, Panikker S, Wong T, Gupta D. Efficacy of catheter ablation for persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized and nonrandomized controlled trials. *Circulation Arrhythmia and electrophysiology* Oct 2014;7:841-852.
236. Kainuma S, Masai T, Yoshitatsu M, Miyagawa S, Yamauchi T, Takeda K, Morii E, Sawa Y. Advanced left-atrial fibrosis is associated with unsuccessful maze operation for valvular atrial fibrillation. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery* Jul 2011;40:61-69.
237. Hartono B, Lo LW, Cheng CC, et al. A novel finding of the atrial substrate properties and long-term results of catheter ablation in chronic atrial fibrillation patients with left atrial spontaneous echo contrast. *Journal of cardiovascular electrophysiology* Mar 2012;23:239-246.
238. Fiala M, Bulkova V, Sknouril L, Nevalova R, Toman O, Januska J, Spinar J, Wichterle D. Sinus rhythm restoration and arrhythmia noninducibility are major predictors of arrhythmia-free outcome after ablation for long-standing persistent atrial fibrillation: A prospective study. *Heart rhythm : the official journal of the Heart Rhythm Society* Apr 2015;12:687-698.
239. Budera P, Straka Z, Osmancik P, Vanek T, Jelinek S, Hlavicka J, Fojt R, Cervinka P, Hulman M, Smid M, Maly M, Widimsky P. Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study. *European heart journal* Nov 2012;33:2644-2652.
240. Yoshida K, Chugh A, Good E, et al. A critical decrease in dominant frequency and clinical outcome after catheter ablation of persistent atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Mar 2010;7:295-302.
241. Nagamoto Y, Park JS, Tanubudi D, Ko YK, Ban JE, Kwak JJ, Choi JJ, Lim HE, Park SW, Kim YH. Clinical significance of induced atrial tachycardia after termination of longstanding persistent atrial fibrillation using a stepwise approach. *Journal of cardiovascular electrophysiology* Nov 2012;23:1171-1178.
242. Elayi CS, Di Biase L, Barrett C, et al. Atrial fibrillation termination as a procedural endpoint during ablation in long-standing persistent atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Sep 2010;7:1216-1223.
243. Komatsu Y, Taniguchi H, Miyazaki S, Nakamura H, Kusa S, Uchiyama T, Kakita K, Kakuta T, Hachiya H, Iesaka Y. Impact of atrial fibrillation termination on clinical outcome after ablation in relation to the duration of persistent atrial fibrillation. *Pacing and clinical electrophysiology : PACE* Dec 2012;35:1436-1443.
244. Fassini G, Riva S, Chiodelli R, Trevisi N, Berti M, Carubicchio C, Maccabelli G, Giraldi F, Bella PD. Left mitral isthmus ablation associated with PV Isolation: long-term results of a prospective randomized study. *Journal of cardiovascular electrophysiology* Nov 2005;16:1150-1156.
245. Haissaguerre M, Sanders P, Hocini M, et al. Catheter ablation of long-lasting persistent atrial fibrillation: critical structures for termination. *Journal of cardiovascular electrophysiology* Nov 2005;16:1125-1137.
246. Gaita F, Caponi D, Scaglione M, Montefusco A, Corleto A, Di Monte F, Coin D, Di Donna P, Giustetto C. Long-term clinical results of 2 different ablation strategies in patients with paroxysmal and persistent atrial fibrillation. *Circulation Arrhythmia and electrophysiology* Oct 2008;1:269-275.
247. Kim JS, Shin SY, Na JO, et al. Does isolation of the left atrial posterior wall improve clinical outcomes after radiofrequency catheter ablation for persistent atrial fibrillation?: A prospective randomized clinical trial. *International journal of cardiology* Feb 15 2015;181:277-283.
248. Bai R, Di Biase L, Mohanty P, et al. Proven isolation of the pulmonary vein antrum with or without left atrial posterior wall isolation in patients with persistent atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Aug 13 2015.
249. Nademanee K, McKenzie J, Kosar E, Schwab M, Sunsaneewitayakul B, Vasavakul T, Khunnawat C, Ngarmukos T. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. *Journal of the American College of Cardiology* Jun 2 2004;43:2044-2053.
250. Oral H, Chugh A, Lemola K, Cheung P, Hall B, Good E, Han J, Tamirisa K, Bogun F, Pelosi F, Jr., Morady F. Noninducibility of atrial fibrillation as an end point of left atrial circumferential ablation for paroxysmal atrial fibrillation: a randomized study. *Circulation* Nov 2 2004;110:2797-2801.
251. Lin YJ, Tai CT, Chang SL, et al. Efficacy of additional ablation of complex fractionated atrial electrograms for catheter ablation of nonparoxysmal atrial fibrillation. *Journal of cardiovascular electrophysiology* Jun 2009;20:607-615.
252. Bai R, Di Biase L, Mohanty P, et al. Ablation of perimitral flutter following catheter ablation of atrial fibrillation: impact on outcomes from a randomized study (PROPOSE). *Journal of cardiovascular electrophysiology* Feb 2012;23:137-144.
253. Kumagai K, Sakamoto T, Nakamura K, Nishiuchi S, Hayano M, Hayashi T, Sasaki T, Aonuma K, Oshima S. Combined dominant frequency and complex fractionated atrial electrogram ablation after circumferential pulmonary vein isolation of atrial fibrillation. *Journal of cardiovascular electrophysiology* Sep 2013;24:975-983.
254. Lemola K, Chartier D, Yeh YH, Dubuc M, Cartier R, Armour A, Ting M, Sakabe M, Shiroshita-Takeshita A, Comtois P, Nattel S. Pulmonary vein region ablation in experimental vagal atrial fibrillation: role of pulmonary veins versus autonomic ganglia. *Circulation* Jan 29 2008;117:470-477.
255. Narayan SM, Patel J, Mulpuru S, Krummen DE. Focal impulse and rotor modulation ablation of sustaining rotors abruptly terminates persistent atrial fibrillation to sinus rhythm with elimination on follow-up: a video case study. *Heart rhythm : the official journal of the Heart Rhythm Society* Sep 2012;9:1436-1439.
256. Jais P, Hocini M, Hsu LF, et al. Technique and results of linear ablation at the mitral isthmus. *Circulation* Nov 9 2004;110:2996-3002.
257. Yokokawa M, Sundaram B, Garg A, Stojanovska J, Oral H, Morady F, Chugh A. Impact of mitral isthmus anatomy on the likelihood of achieving linear block in patients undergoing catheter ablation of persistent atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Sep 2011;8:1404-1410.
258. Hocini M, Shah AJ, Nault I, et al. Mitral isthmus ablation with and without temporary spot occlusion of the coronary sinus: a randomized clinical comparison of acute outcomes. *Journal of cardiovascular electrophysiology* May 2012;23:489-496.
259. D'Avila A, Thiagalingam A, Foley L, Fox M, Ruskin JN, Reddy VY. Temporary occlusion of the great cardiac vein and coronary sinus to facilitate radiofrequency catheter ablation of the mitral isthmus. *Journal of cardiovascular electrophysiology* Jun 2008;19:645-650.
260. Sawhney N, Anand K, Robertson CE, Wurdeman T, Anousheh R, Feld GK. Recovery of mitral isthmus conduction leads to the development of macro-reentrant tachycardia after left atrial linear ablation for atrial fibrillation. *Circulation Arrhythmia and electrophysiology* Dec 2011;4:832-837.
261. Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent

- atrial fibrillation. *The New England journal of medicine* May 7 2015;372:1812-1822.
262. Wazni O, Marrouche NF, Martin DO, et al. Randomized study comparing combined pulmonary vein-left atrial junction disconnection and cavotricuspid isthmus ablation versus pulmonary vein-left atrial junction disconnection alone in patients presenting with typical atrial flutter and atrial fibrillation. *Circulation* Nov 18 2003;108:2479-2483.
  263. Pontoppidan J, Nielsen JC, Poulsen SH, Jensen HK, Walfridsson H, Pedersen AK, Hansen PS. Prophylactic cavotricuspid isthmus block during atrial fibrillation ablation in patients without atrial flutter: a randomised controlled trial. *Heart Jun 2009;95:994-999*.
  264. Chugh A, Latchamsetty R, Oral H, Elmouchi D, Tschopp D, Reich S, Iqbal P, Lemerand T, Good E, Bogun F, Pelosi F, Jr., Morady F. Characteristics of cavotricuspid isthmus-dependent atrial flutter after left atrial ablation of atrial fibrillation. *Circulation* Feb 7 2006;113:609-615.
  265. Shah DC, Sunthorn H, Burri H, Gentil-Baron P. Evaluation of an individualized strategy of cavotricuspid isthmus ablation as an adjunct to atrial fibrillation ablation. *Journal of cardiovascular electrophysiology* Sep 2007;18:926-930.
  266. Phan K, Xie A, Tsai YC, Kumar N, La Meir M, Yan TD. Biatrial ablation vs. left atrial concomitant surgical ablation for treatment of atrial fibrillation: a meta-analysis. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* Jan 2015;17:38-47.
  267. Oral H, Chugh A, Yoshida K, et al. A randomized assessment of the incremental role of ablation of complex fractionated atrial electrograms after antral pulmonary vein isolation for long-lasting persistent atrial fibrillation. *Journal of the American College of Cardiology* Mar 3 2009;53:782-789.
  268. Nakahara S, Kamijima T, Hori Y, Tsukada N, Okano A, Takayanagi K. Substrate modification by adding ablation of localized complex fractionated electrograms after stepwise linear ablation in persistent atrial fibrillation. *Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing* Mar 2014;39:121-129.
  269. Lemola K, Ting M, Gupta P, et al. Effects of two different catheter ablation techniques on spectral characteristics of atrial fibrillation. *Journal of the American College of Cardiology* Jul 18 2006;48:340-348.
  270. Takahashi Y, O'Neill MD, Hocini M, et al. Characterization of electrograms associated with termination of chronic atrial fibrillation by catheter ablation. *Journal of the American College of Cardiology* Mar 11 2008;51:1003-1010.
  271. Lin YJ, Tai CT, Kao T, et al. Spatiotemporal organization of the left atrial substrate after circumferential pulmonary vein isolation of atrial fibrillation. *Circulation Arrhythmia and electrophysiology* Jun 2009;2:233-241.
  272. Hunter RJ, Diab I, Tayebjee M, Richmond L, Sporton S, Earley MJ, Schilling RJ. Characterization of fractionated atrial electrograms critical for maintenance of atrial fibrillation: a randomized, controlled trial of ablation strategies (the CFAE AF trial). *Circulation Arrhythmia and electrophysiology* Oct 2011;4:622-629.
  273. Verma A, Sanders P, Champagne J, Macle L, Nair GM, Calkins H, Wilber DJ. Selective complex fractionated atrial electrograms targeting for atrial fibrillation study (SELECT AF): a multicenter, randomized trial. *Circulation Arrhythmia and electrophysiology* Feb 2014;7:55-62.
  274. Tuan J, Jeilan M, Kundu S, Nicolson W, Chung I, Stafford PJ, Ng GA. Regional fractionation and dominant frequency in persistent atrial fibrillation: effects of left atrial ablation and evidence of spatial relationship. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* Nov 2011;13:1550-1556.
  275. Han SW, Shin SY, Im SI, et al. Does the amount of atrial mass reduction improve clinical outcomes after radiofrequency catheter ablation for long-standing persistent atrial fibrillation? Comparison between linear ablation and defragmentation. *International journal of cardiology* Jan 15 2014;171:37-43.
  276. Estner HL, Hessling G, Biegler R, Schreieck J, Fichtner S, Wu J, Jilek C, Zrenner B, Ndrepepa G, Schmitt C, Deisenhofer I. Complex fractionated atrial electrogram or linear ablation in patients with persistent atrial fibrillation--a prospective randomized study. *Pacing and clinical electrophysiology : PACE* Aug 2011;34:939-948.
  277. Haissaguerre M, Hocini M, Sanders P, et al. Localized sources maintaining atrial fibrillation organized by prior ablation. *Circulation* Feb 7 2006;113:616-625.
  278. Dibs SR, Ng J, Arora R, Passman RS, Kadish AH, Goldberger JJ. Spatiotemporal characterization of atrial activation in persistent human atrial fibrillation: multisite electrogram analysis and surface electrocardiographic correlations--a pilot study. *Heart rhythm : the official journal of the Heart Rhythm Society* May 2008;5:686-693.
  279. Narayan SM, Krummen DE, Rappel WJ. Clinical mapping approach to diagnose electrical rotors and focal impulse sources for human atrial fibrillation. *Journal of cardiovascular electrophysiology* May 2012;23:447-454.
  280. Narayan SM, Krummen DE, Clopton P, Shivkumar K, Miller JM. Direct or coincidental elimination of stable rotors or focal sources may explain successful atrial fibrillation ablation: on-treatment analysis of the CONFIRM trial (Conventional ablation for AF with or without focal impulse and rotor modulation). *Journal of the American College of Cardiology* Jul 9 2013;62:138-147.
  281. Narayan SM, Baykaner T, Clopton P, Schrickler A, Lalani GG, Krummen DE, Shivkumar K, Miller JM. Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared with trigger ablation alone: extended follow-up of the CONFIRM trial (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation). *Journal of the American College of Cardiology* May 6 2014;63:1761-1768.
  282. Jones AR, Krummen DE, Narayan SM. Non-invasive identification of stable rotors and focal sources for human atrial fibrillation: mechanistic classification of atrial fibrillation from the electrocardiogram. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* Sep 2013;15:1249-1258.
  283. Guillem MS, Climent AM, Millet J, Arenal A, Fernandez-Aviles F, Jalife J, Atienza F, Berenfeld O. Noninvasive localization of maximal frequency sites of atrial fibrillation by body surface potential mapping. *Circulation Arrhythmia and electrophysiology* Apr 2013;6:294-301.
  284. Misiri J, Asirvatham SJ. Can we isolate the pulmonary veins? *Heart rhythm : the official journal of the Heart Rhythm Society* Apr 2014;11:557-558.
  285. Scharf C, Sneider M, Case I, Chugh A, Lai SW, Pelosi F, Jr., Knight BP, Kazerooni E, Morady F, Oral H. Anatomy of the pulmonary veins in patients with atrial fibrillation and effects of segmental ostial ablation analyzed by computed tomography. *Journal of cardiovascular electrophysiology* Feb 2003;14:150-155.
  286. Markides V, Schilling RJ, Ho SY, Chow AW, Davies DW, Peters NS. Characterization of left atrial activation in the intact human heart. *Circulation* Feb 11 2003;107:733-739.
  287. Chang SL, Tai CT, Lin YJ, et al. The role of left atrial muscular bundles in catheter ablation of atrial fibrillation. *Journal of the American College of Cardiology* Sep 4 2007;50:964-973.
  288. Roberts-Thomson KC, Stevenson I, Kistler PM, Haqqani HM, Spence SJ, Goldblatt JC, Sanders P, Kalman JM. The role of chronic atrial stretch and atrial fibrillation on posterior left atrial wall conduction. *Heart rhythm : the official journal of the Heart Rhythm Society* Aug 2009;6:1109-1117.
  289. Tagawa M, Higuchi K, Chinushi M, Washizuka T, Ushiki T, Ishihara N, Aizawa Y. Myocardium extending from the left atrium onto the pulmonary veins: a comparison between subjects with and without atrial fibrillation. *Pacing and clinical electrophysiology : PACE* Oct 2001;24:1459-1463.
  290. Tanaka K, Zlochiver S, Vikstrom KL, et al. Spatial distribution of fibrosis

- governs fibrillation wave dynamics in the posterior left atrium during heart failure. *Circulation research* Oct 12 2007;101:839-847.
291. adidi AS, Cochet H, Shah AJ, et al. Inverse relationship between fractionated electrograms and atrial fibrosis in persistent atrial fibrillation: combined magnetic resonance imaging and high-density mapping. *Journal of the American College of Cardiology* Aug 27 2013;62:802-812.
  292. Scherlag BJ, Yamanashi W, Patel U, Lazzara R, Jackman WM. Autonomically induced conversion of pulmonary vein focal firing into atrial fibrillation. *Journal of the American College of Cardiology* Jun 7 2005;45:1878-1886.
  293. Hunter RJ, Liu Y, Lu Y, Wang W, Schilling RJ. Left atrial wall stress distribution and its relationship to electrophysiologic remodeling in persistent atrial fibrillation. *Circulation Arrhythmia and electrophysiology* Apr 2012;5:351-360.
  294. Yoshida K, Ulfarsson M, Oral H, Crawford T, Good E, Jongnarangsin K, Bogun F, Pelosi F, Jalife J, Morady F, Chugh A. Left atrial pressure and dominant frequency of atrial fibrillation in humans. *Heart rhythm : the official journal of the Heart Rhythm Society* Feb 2011;8:181-187.
  295. Munger TM, Dong YX, Masaki M, et al. Electrophysiological and hemodynamic characteristics associated with obesity in patients with atrial fibrillation. *Journal of the American College of Cardiology* Aug 28 2012;60:851-860.
  296. Takahashi Y, O'Neill MD, Hocini M, et al. Effects of stepwise ablation of chronic atrial fibrillation on atrial electrical and mechanical properties. *Journal of the American College of Cardiology* Mar 27 2007;49:1306-1314.
  297. Rolf S, Kircher S, Arya A, Eitel C, Sommer P, Richter S, Gaspar T, Bollmann A, Altmann D, Piedra C, Hindricks G, Piorkowski C. Tailored atrial substrate modification based on low-voltage areas in catheter ablation of atrial fibrillation. *Circulation Arrhythmia and electrophysiology* Oct 2014;7:825-833.
  298. Kofune M, Okumura Y, Watanabe I, Nagashima K, Sonoda K, Mano H, Kogawa R, Sasaki N, Ohkubo K, Nakai T, Nikaido M, Hirayama A. Comparative distribution of complex fractionated atrial electrograms, high dominant frequency (HDF) sites during atrial fibrillation and HDF sites during sinus rhythm. *Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing* Apr 2013;36:297-306.
  299. Lee G, Roberts-Thomson K, Madry A, Spence S, Teh A, Heck PM, Kumar S, Kistler PM, Morton JB, Sanders P, Kalman JM. Relationship among complex signals, short cycle length activity, and dominant frequency in patients with long-lasting persistent AF: a high-density epicardial mapping study in humans. *Heart rhythm : the official journal of the Heart Rhythm Society* Nov 2011;8:1714-1719.
  300. Nakahara S, Toratani N, Nakamura H, Higashi A, Takayanagi K. Spatial relationship between high-dominant-frequency sites and the linear ablation line in persistent atrial fibrillation: its impact on complex fractionated electrograms. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* Feb 2013;15:189-197.
  301. Singh SM, Heist EK, Koruth JS, Barrett CD, Ruskin JN, Mansour MC. The relationship between electrogram cycle length and dominant frequency in patients with persistent atrial fibrillation. *Journal of cardiovascular electrophysiology* Dec 2009;20:1336-1342.
  302. Ghoraani B, Dalvi R, Gizurason S, Das M, Ha A, Suszko A, Krishnan S, Chauhan VS. Localized rotational activation in the left atrium during human atrial fibrillation: relationship to complex fractionated atrial electrograms and low-voltage zones. *Heart rhythm : the official journal of the Heart Rhythm Society* Dec 2013;10:1830-1838.
  303. Salinet JL, Tuan JH, Sandilands AJ, Stafford PJ, Schlindwein FS, Ng GA. Distinctive patterns of dominant frequency trajectory behavior in drug-refractory persistent atrial fibrillation: preliminary characterization of spatiotemporal instability. *Journal of cardiovascular electrophysiology* Apr 2014;25:371-379.
  304. Miller JM, Kowal RC, Swarup V, et al. Initial independent outcomes from focal impulse and rotor modulation ablation for atrial fibrillation: multicenter FIRM registry. *Journal of cardiovascular electrophysiology* Sep 2014;25:921-929.
  305. Hong KN, Russo MJ, Liberman EA, Trzebecki A, Oz MC, Argenziano M, Williams MR. Effect of epicardial fat on ablation performance: a three-energy source comparison. *Journal of cardiac surgery* Nov-Dec 2007;22:521-524.
  306. Berjano EJ, Hornero F. Thermal-electrical modeling for epicardial atrial radiofrequency ablation. *IEEE transactions on bio-medical engineering* Aug 2004;51:1348-1357.
  307. Sakamoto S, Voeller RK, Melby SJ, Lall SC, Chang NL, Schuessler RB, Damiano RJ, Jr. Surgical ablation for atrial fibrillation: the efficacy of a novel bipolar pen device in the cardioplegically arrested and beating heart. *The Journal of thoracic and cardiovascular surgery* Nov 2008;136:1295-1301.
  308. Beinart R, Abbara S, Blum A, Ferencik M, Heist K, Ruskin J, Mansour M. Left atrial wall thickness variability measured by CT scans in patients undergoing pulmonary vein isolation. *Journal of cardiovascular electrophysiology* Nov 2011;22:1232-1236.
  309. Lemola K, Sneider M, Desjardins B, et al. Computed tomographic analysis of the anatomy of the left atrium and the esophagus: implications for left atrial catheter ablation. *Circulation* Dec 14 2004;110:3655-3660.
  310. den Uijl DW, Tops LF, Delgado V, Schuijff JD, Kroft LJ, de Roos A, Boersma E, Trines SA, Zeppenfeld K, Schalij MJ, Bax JJ. Effect of pulmonary vein anatomy and left atrial dimensions on outcome of circumferential radiofrequency catheter ablation for atrial fibrillation. *The American journal of cardiology* Jan 15 2011;107:243-249.
  311. McLellan AJ, Ling LH, Ruggiero D, Wong MC, Walters TE, Nisbet A, Shetty AK, Azzopardi S, Taylor AJ, Morton JB, Kalman JM, Kistler PM. Pulmonary vein isolation: the impact of pulmonary venous anatomy on long-term outcome of catheter ablation for paroxysmal atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Apr 2014;11:549-556.
  312. Avital B, Mughal K, Hare J, Helms R, Krum D. The effects of electrode-tissue contact on radiofrequency lesion generation. *Pacing and clinical electrophysiology : PACE* Dec 1997;20:2899-2910.
  313. Okumura Y, Johnson SB, Bunch TJ, Henz BD, O'Brien CJ, Packer DL. A systematical analysis of in vivo contact forces on virtual catheter tip/tissue surface contact during cardiac mapping and intervention. *Journal of cardiovascular electrophysiology* Jun 2008;19:632-640.
  314. Hindricks G, Haverkamp W, Gulker H, Rissel U, Budde T, Richter KD, Borggrefe M, Breithardt G. Radiofrequency coagulation of ventricular myocardium: improved prediction of lesion size by monitoring catheter tip temperature. *European heart journal* Nov 1989;10:972-984.
  315. Nakagawa H, Wittkampf FH, Yamanashi WS, Pitha JV, Imai S, Campbell B, Arruda M, Lazzara R, Jackman WM. Inverse relationship between electrode size and lesion size during radiofrequency ablation with active electrode cooling. *Circulation* Aug 4 1998;98:458-465.
  316. Chan RC, Johnson SB, Seward JB, Packer DL. The effect of ablation electrode length and catheter tip to endocardial orientation on radiofrequency lesion size in the canine right atrium. *Pacing and clinical electrophysiology : PACE* Jan 2002;25:4-13.
  317. Wood MA, Goldberg SM, Parvez B, Pathak V, Holland K, Ellenbogen AL, Han FT, Alexander D, Lau M, Reshko L, Goel A. Effect of electrode orientation on lesion sizes produced by irrigated radiofrequency ablation catheters. *Journal of cardiovascular electrophysiology* Nov 2009;20:1262-1268.
  318. Nakagawa H, Yamanashi WS, Pitha JV, Arruda M, Wang X, Ohtomo K, Beckman KJ, McClelland JH, Lazzara R, Jackman WM. Comparison of in vivo tissue temperature profile and lesion geometry for radiofrequency ablation with a saline-irrigated electrode versus temperature control in a canine thigh muscle preparation. *Circulation* Apr 15 1995;91:2264-2273.
  319. d'Avila A, Houghtaling C, Gutierrez P, Vragovic O, Ruskin JN, Josephson ME, Reddy VY. Catheter ablation of ventricular epicardial tissue: a comparison

- of standard and cooled-tip radiofrequency energy. *Circulation* May 18 2004;109:2363-2369.
320. Fuller IA, Wood MA. Intramural coronary vasculature prevents transmural radiofrequency lesion formation: implications for linear ablation. *Circulation* Apr 8 2003;107:1797-1803.
321. Mesas CE, Augello G, Lang CC, Gugliotta F, Vicedomini G, Sora N, De Paola AA, Pappone C. Electroanatomic remodeling of the left atrium in patients undergoing repeat pulmonary vein ablation: mechanistic insights and implications for ablation. *Journal of cardiovascular electrophysiology* Dec 2006;17:1279-1285.
322. Neuzil P, Reddy VY, Kautzner J, Petru J, Wichterle D, Shah D, Lambert H, Yulzari A, Wissner E, Kuck KH. Electrical reconnection after pulmonary vein isolation is contingent on contact force during initial treatment: results from the EFFICAS I study. *Circulation Arrhythmia and electrophysiology* Apr 2013;6:327-333.
323. Makimoto H, Lin T, Rillig A, et al. In vivo contact force analysis and correlation with tissue impedance during left atrial mapping and catheter ablation of atrial fibrillation. *Circulation Arrhythmia and electrophysiology* Feb 2014;7:46-54.
324. Schwartzman D, Ren JF, Devine WA, Callans DJ. Cardiac swelling associated with linear radiofrequency ablation in the atrium. *Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing* Jun 2001;5:159-166.
325. Kowalski M, Grimes MM, Perez FJ, Kenigsberg DN, Koneru J, Kasirajan V, Wood MA, Ellenbogen KA. Histopathologic characterization of chronic radiofrequency ablation lesions for pulmonary vein isolation. *Journal of the American College of Cardiology* Mar 6 2012;59:930-938.
326. Yamane T, Matsuo S, Date T, et al. Repeated provocation of time- and ATP-induced early pulmonary vein reconnections after pulmonary vein isolation: eliminating paroxysmal atrial fibrillation in a single procedure. *Circulation Arrhythmia and electrophysiology* Oct 2011;4:601-608.
327. Arentz T, Macle L, Kalusche D, Hocini M, Jais P, Shah D, Haissaguerre M. "Dormant" pulmonary vein conduction revealed by adenosine after ostial radiofrequency catheter ablation. *Journal of cardiovascular electrophysiology* Sep 2004;15:1041-1047.
328. Andrade JG, Pollak SJ, Monir G, et al. Pulmonary vein isolation using a pace-capture-guided versus an adenosine-guided approach: effect on dormant conduction and long-term freedom from recurrent atrial fibrillation--a prospective study. *Circulation Arrhythmia and electrophysiology* Dec 2013;6:1103-1108.
329. Steven D, Sultan A, Reddy V, Luker J, Altenburg M, Hoffmann B, Rostock T, Servatius H, Stevenson WG, Willems S, Michaud GF. Benefit of pulmonary vein isolation guided by loss of pace capture on the ablation line: results from a prospective 2-center randomized trial. *Journal of the American College of Cardiology* Jul 2 2013;62:44-50.
330. Reddy VY, Shah D, Kautzner J, et al. The relationship between contact force and clinical outcome during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA study. *Heart rhythm : the official journal of the Heart Rhythm Society* Nov 2012;9:1789-1795.
331. Natale A, Reddy VY, Monir G, et al. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. *Journal of the American College of Cardiology* Aug 19 2014;64:647-656.
332. Andrade JG, Monir G, Pollak SJ, et al. Pulmonary vein isolation using "contact force" ablation: the effect on dormant conduction and long-term freedom from recurrent atrial fibrillation--a prospective study. *Heart rhythm : the official journal of the Heart Rhythm Society* Nov 2014;11:1919-1924.
333. Miller MA, d'Avila A, Dukkupati SR, Koruth JS, Viles-Gonzalez J, Napolitano C, Eggert C, Fischer A, Gomes JA, Reddy VY. Acute electrical isolation is a necessary but insufficient endpoint for achieving durable PV isolation: the importance of closing the visual gap. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* May 2012;14:653-660.
334. Anter E, Tschabrunn CM, Contreras-Valdes FM, Buxton AE, Josephson ME. Radiofrequency ablation annotation algorithm reduces the incidence of linear gaps and reconnection after pulmonary vein isolation. *Heart rhythm : the official journal of the Heart Rhythm Society* May 2014;11:783-790.
335. Lachman N, Syed FF, Habib A, Kapa S, Bisco SE, Venkatachalam KL, Asirvatham SJ. Correlative anatomy for the electrophysiologist, Part I: the pericardial space, oblique sinus, transverse sinus. *Journal of cardiovascular electrophysiology* Dec 2010;21:1421-1426.
336. Aoyama H, Nakagawa H, Pitha JV, Khammar GS, Chandrasekaran K, Matsudaira K, Yagi T, Yokoyama K, Lazzara R, Jackman WM. Comparison of cryothermia and radiofrequency current in safety and efficacy of catheter ablation within the canine coronary sinus close to the left circumflex coronary artery. *Journal of cardiovascular electrophysiology* Nov 2005;16:1218-1226.
337. Thomas SP, Guy DJ, Boyd AC, Eipper VE, Ross DL, Chard RB. Comparison of epicardial and endocardial linear ablation using handheld probes. *The Annals of thoracic surgery* Feb 2003;75:543-548.
338. Stojanovska J, Kazerooni EA, Sinno M, Gross BH, Watcharotone K, Patel S, Jacobson JA, Oral H. Increased epicardial fat is independently associated with the presence and chronicity of atrial fibrillation and radiofrequency ablation outcome. *European radiology* Mar 13 2015.
339. Prasad SM, Maniar HS, Schuessler RB, Damiano RJ, Jr. Chronic transmural atrial ablation by using bipolar radiofrequency energy on the beating heart. *The Journal of thoracic and cardiovascular surgery* Oct 2002;124:708-713.
340. La Meir M, Gelsomino S, Luca F, Lorusso R, Gensini GF, Pison L, Wellens F, Maessen J. Minimally invasive thoracoscopic hybrid treatment of lone atrial fibrillation: early results of monopolar versus bipolar radiofrequency source. *Interactive cardiovascular and thoracic surgery* Apr 2012;14:445-450.
341. Voeller RK, Zierer A, Lall SC, Sakamoto S, Schuessler RB, Damiano RJ, Jr. Efficacy of a novel bipolar radiofrequency ablation device on the beating heart for atrial fibrillation ablation: a long-term porcine study. *The Journal of thoracic and cardiovascular surgery* Jul 2010;140:203-208.
342. Coumel P, Attuel P, Lavallee J, Flammang D, Leclercq JF, Slama R. [The atrial arrhythmia syndrome of vagal origin]. *Archives des maladies du coeur et des vaisseaux* Jun 1978;71:645-656.
343. Vaitkevicius R, Saburkina I, Rysevaite K, Vaitkeviciene I, Pauziene N, Zaliunas R, Schauerte P, Jalife J, Pauza DH. Nerve supply of the human pulmonary veins: an anatomical study. *Heart rhythm : the official journal of the Heart Rhythm Society* Feb 2009;6:221-228.
344. Kapa S, Venkatachalam KL, Asirvatham SJ. The autonomic nervous system in cardiac electrophysiology: an elegant interaction and emerging concepts. *Cardiology in review* Nov-Dec 2010;18:275-284.
345. Patterson E, Po SS, Scherlag BJ, Lazzara R. Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation. *Heart rhythm : the official journal of the Heart Rhythm Society* Jun 2005;2:624-631.
346. Onorati F, Curcio A, Santarpino G, Torella D, Mastroberto P, Tucci L, Indolfi C, Renzulli A. Routine ganglionic plexi ablation during Maze procedure improves hospital and early follow-up results of mitral surgery. *The Journal of thoracic and cardiovascular surgery* Aug 2008;136:408-418.
347. Chugh A. Ganglionated plexus ablation in patients undergoing pulmonary vein isolation for paroxysmal atrial fibrillation: here we go again. *Journal of the American College of Cardiology* Dec 17 2013;62:2326-2328.
348. Zhou Q, Hou Y, Yang S. A meta-analysis of the comparative efficacy of ablation for atrial fibrillation with and without ablation of the ganglionated plexi. *Pacing and clinical electrophysiology : PACE* Dec 2011;34:1687-1694.
349. Oh S, Zhang Y, Bibevski S, Marrouche NF, Natale A, Mazgalev TN. Vagal denervation and atrial fibrillation inducibility: epicardial fat pad ablation does not have long-term effects. *Heart rhythm : the official journal of the Heart Rhythm*

Society Jun 2006;3:701-708.

350. Mao J, Yin X, Zhang Y, Yan Q, Dong J, Ma C, Liu X. Ablation of epicardial ganglionated plexi increases atrial vulnerability to arrhythmias in dogs. *Circulation Arrhythmia and electrophysiology* Aug 2014;7:711-717.
351. Syed FF, DeSimone CV, Friedman PA, Asirvatham SJ. Left atrial appendage exclusion for atrial fibrillation. *Cardiology clinics* Nov 2014;32:601-625.
352. Cox JL, Ad N, Palazzo T. Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. *The Journal of thoracic and cardiovascular surgery* Nov 1999;118:833-840.
353. Buber J, Luria D, Sternik L, Raanani E, Feinberg MS, Goldenberg I, Nof E, Gurevitz O, Eldar M, Glikson M, Kuperstein R. Left atrial contractile function following a successful modified Maze procedure at surgery and the risk for subsequent thromboembolic stroke. *Journal of the American College of Cardiology* Oct 4 2011;58:1614-1621.
354. Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS, Anderson JL, Muhlestein JB, Horne BD, Lappe DL, Day JD. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. *Journal of cardiovascular electrophysiology* Aug 2011;22:839-845.
355. Di Biase L, Santangeli P, Anselmino M, et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. *Journal of the American College of Cardiology* Aug 7 2012;60:531-538.
356. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P, Investigators PA. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. *Lancet* Aug 15 2009;374:534-542.
357. Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery* Jul 26 2014.
358. Syed FF, Asirvatham SJ. Left atrial appendage as a target for reducing strokes: justifiable rationale? Safe and effective approaches? *Heart rhythm : the official journal of the Heart Rhythm Society* Feb 2011;8:194-198.
359. Tabata T, Oki T, Yamada H, Iuchi A, Ito S, Hori T, Kitagawa T, Kato I, Kitahata H, Oshita S. Role of left atrial appendage in left atrial reservoir function as evaluated by left atrial appendage clamping during cardiac surgery. *The American journal of cardiology* Feb 1 1998;81:327-332.
360. Lee CH, Kim JB, Jung SH, Choo SJ, Chung CH, Lee JW. Left atrial appendage resection versus preservation during the surgical ablation of atrial fibrillation. *The Annals of thoracic surgery* Jan 2014;97:124-132.
361. Syed FF, Rangu V, Bruce CJ, et al. Percutaneous ligation of the left atrial appendage results in atrial electrical substrate modification. *Translational research : the journal of laboratory and clinical medicine* Mar 2015;165:365-373.
362. Hocini M, Shah AJ, Nault I, et al. Localized reentry within the left atrial appendage: arrhythmogenic role in patients undergoing ablation of persistent atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Dec 2011;8:1853-1861.
363. Yamada T, Murakami Y, Yoshida Y, et al. Electrophysiologic and electrocardiographic characteristics and radiofrequency catheter ablation of focal atrial tachycardia originating from the left atrial appendage. *Heart rhythm : the official journal of the Heart Rhythm Society* Oct 2007;4:1284-1291.
364. Chan CP, Wong WS, Pumphrey S, et al. Inadvertent electrical isolation of the left atrial appendage during catheter ablation of persistent atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* 2010;7:173-180.
365. Khan MN, Jais P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. *The New England journal of medicine* Oct 23 2008;359:1778-1785.
366. Ling LH, Taylor AJ, Ellims AH, et al. Sinus rhythm restores ventricular function in patients with cardiomyopathy and no late gadolinium enhancement on cardiac magnetic resonance imaging who undergo catheter ablation for atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Sep 2013;10:1334-1339.
367. Tops LF, Den Uijl DW, Delgado V, Marsan NA, Zeppenfeld K, Holman E, van der Wall EE, Schalij MJ, Bax JJ. Long-term improvement in left ventricular strain after successful catheter ablation for atrial fibrillation in patients with preserved left ventricular systolic function. *Circulation Arrhythmia and electrophysiology* Jun 2009;2:249-257.
368. Stulak JM, Dearani JA, Daly RC, Zehr KJ, Sundt TM, 3rd, Schaff HV. Left ventricular dysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-maze procedure significantly improves systolic function and functional status. *The Annals of thoracic surgery* Aug 2006;82:494-500; discussion 500-491.
369. Tse HF, Lau CP, Yu CM, Lee KL, Michaud GF, Knight BP, Morady F, Strickberger SA. Effect of the implantable atrial defibrillator on the natural history of atrial fibrillation. *Journal of cardiovascular electrophysiology* Sep 1999;10:1200-1209.
370. Igarashi M, Tada H, Sekiguchi Y, Yamasaki H, Arimoto T, Kuroki K, Machino T, Murakoshi N, Aonuma K. Effect of restoration of sinus rhythm by extensive antiarrhythmic drugs in predicting results of catheter ablation of persistent atrial fibrillation. *The American journal of cardiology* Jul 1 2010;106:62-68.
371. Feinberg MS, Waggoner AD, Kater KM, Cox JL, Lindsay BD, Perez JE. Restoration of atrial function after the maze procedure for patients with atrial fibrillation. Assessment by Doppler echocardiography. *Circulation* Nov 1994;90:II285-292.
372. Lonnerholm S, Blomstrom P, Nilsson L, Blomstrom-Lundqvist C. Long-term effects of the maze procedure on atrial size and mechanical function. *The Annals of thoracic surgery* Mar 2008;85:916-920.
373. Sheldon SH, Bois JP, Stulak JM, Ammash NM, Brady PA, Lin G. Surgical treatment of atrial fibrillation: effects of different techniques on atrial mechanical function [abstract]. *Circulation* Nov 26 2013;128.
374. Welch TD, Coylewright M, Powell BD, Asirvatham SJ, Gersh BJ, Dearani JA, Nishimura RA. Symptomatic pulmonary hypertension with giant left atrial v waves after surgical maze procedures: evaluation by comprehensive hemodynamic catheterization. *Heart rhythm : the official journal of the Heart Rhythm Society* Dec 2013;10:1839-1842.
375. Gibson DN, Di Biase L, Mohanty P, et al. Stiff left atrial syndrome after catheter ablation for atrial fibrillation: clinical characterization, prevalence, and predictors. *Heart rhythm : the official journal of the Heart Rhythm Society* Sep 2011;8:1364-1371.
376. Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. *Circulation Arrhythmia and electrophysiology* Feb 2010;3:32-38.
377. Providencia R, Marijon E, Combes S, Bouzeman A, Jourda F, Khoeiry Z, Cardin C, Combes N, Boveda S, Albenque JP. Higher contact-force values associated with better mid-term outcome of paroxysmal atrial fibrillation ablation using the SmartTouch catheter. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* Jan 2015;17:56-63.
378. Squara F, Zhao A, Marijon E, et al. Comparison between radiofrequency with contact force-sensing and second-generation cryoballoon for paroxysmal atrial fibrillation catheter ablation: a multicentre European evaluation. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* Apr 2 2015.
379. Ciconte G, de Asmundis C, Sieira J, et al. Single 3-minute freeze for second-

- generation cryoballoon ablation: One-year follow-up after pulmonary vein isolation. *Heart rhythm : the official journal of the Heart Rhythm Society* Apr 2015;12:673-680.
380. Wokhlu A, Monahan KH, Hodge DO, Asirvatham SJ, Friedman PA, Munger TM, Bradley DJ, Bluhm CM, Haroldson JM, Packer DL. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. *Journal of the American College of Cardiology* May 25 2010;55:2308-2316.
381. Tilz RR, Rillig A, Thum AM, Arya A, Wohlmuth P, Metzner A, Mathew S, Yoshiga Y, Wissner E, Kuck KH, Ouyang F. Catheter ablation of long-standing persistent atrial fibrillation: 5-year outcomes of the Hamburg Sequential Ablation Strategy. *Journal of the American College of Cardiology* Nov 6 2012;60:1921-1929.
382. Schreiber D, Rostock T, Frohlich M, et al. Five-Year Follow Up after Catheter Ablation of Persistent Atrial Fibrillation using the "Stepwise Approach" and Prognostic Factors for Success. *Circulation Arrhythmia and electrophysiology* Mar 5 2015.
383. Deshmukh A, Patel NJ, Pant S, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. *Circulation* Nov 5 2013;128:2104-2112.
384. Shah RU, Freeman JV, Shilane D, Wang PJ, Go AS, Hlatky MA. Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. *Journal of the American College of Cardiology* Jan 10 2012;59:143-149.
385. Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. *Circulation Arrhythmia and electrophysiology* Aug 2009;2:362-369.
386. Blackhouse G, Assasi N, Xie F, Gabel K, Campbell K, Healey JS, O'Reilly D, Goeree R. Cost-effectiveness of catheter ablation for rhythm control of atrial fibrillation. *International journal of vascular medicine* 2013;2013:262809.
387. Aronsson M, Walfridsson H, Janzon M, et al. The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* Jan 2015;17:48-55.
388. Chan PS, Vijan S, Morady F, Oral H. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. *Journal of the American College of Cardiology* Jun 20 2006;47:2513-2520.
389. Rodgers M, McKenna C, Palmer S, Chambers D, Van Hout S, Golder S, Pepper C, Todd D, Woolacott N. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. *Health technology assessment (Winchester, England)* Nov 2008;12:iii-iv, xi-xiii, 1-198.
390. McKenna C, Palmer S, Rodgers M, Chambers D, Hawkins N, Golder S, Van Hout S, Pepper C, Todd D, Woolacott N. Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom. *Heart* Apr 2009;95:542-549.
391. Noro M, Kujime S, Ito N, Enomoto Y, Nakamura K, Sakai T, Sakata T, Sugi K. Cost effectiveness of radiofrequency catheter ablation vs. medical treatment for atrial fibrillation in Japan. -Cost performance for atrial fibrillation. *Circulation journal : official journal of the Japanese Circulation Society* 2011;75:1860-1866.
392. Neyt M, Van Brabandt H, Devos C. The cost-utility of catheter ablation of atrial fibrillation: a systematic review and critical appraisal of economic evaluations. *BMC cardiovascular disorders* 2013;13:78.
393. Reynolds MR, Lamotte M, Todd D, Khaykin Y, Eggington S, Tsintzos S, Klein G. Cost-effectiveness of cryoballoon ablation for the management of paroxysmal atrial fibrillation. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* May 2014;16:652-659.
394. Boersma LV, Castella M, van Boven W, Berruezo A, Yilmaz A, Nadal M, Sandoval E, Calvo N, Brugada J, Kelder J, Wijffels M, Mont L. Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial. *Circulation* Jan 3 2012;125:23-30.
395. Anderson LH, Black EJ, Civello KC, Martinson MS, Kress DC. Cost-effectiveness of the convergent procedure and catheter ablation for non-paroxysmal atrial fibrillation. *Journal of medical economics* Jul 2014;17:481-491.
396. Stulak JM, Suri RM, Burkhart HM, Daly RC, Dearani JA, Greason KL, Joyce LD, Park SJ, Schaff HV. Surgical ablation for atrial fibrillation for two decades: are the results of new techniques equivalent to the Cox maze III procedure? *The Journal of thoracic and cardiovascular surgery* May 2014;147:1478-1486.
397. Phan K, Xie A, Kumar N, Wong S, Medi C, La Meir M, Yan TD. Comparing energy sources for surgical ablation of atrial fibrillation: a Bayesian network meta-analysis of randomized, controlled trials. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery* Nov 12 2014.
398. Ellis CR, Richardson TD, Shoemaker MB, Whalen SP, Hoff SJ. Abstract 12964: Staged versus Same-Day Thoracoscopic Hybrid Ablation for Persistent Atrial Fibrillation: Identification of Pulmonary Vein Reconnection Following Surgical Ablation. *Circulation* November 25, 2014 2014;130:A12964.
399. Kikuchi K, McDonald AD, Sasano T, Donahue JK. Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. *Circulation* Jan 25 2005;111:264-270.
400. Trappe K, Thomas D, Bikou O, Kelemen K, Lugenbiel P, Voss F, Becker R, Katus HA, Bauer A. Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study. *European heart journal* Jan 2013;34:147-157.
401. Soucek R, Thomas D, Kelemen K, Bikou O, Seyler C, Voss F, Becker R, Koenen M, Katus HA, Bauer A. Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant. *Heart rhythm : the official journal of the Heart Rhythm Society* Feb 2012;9:265-272.
402. Wu CH, Hu YF, Chou CY, Lin YJ, Chang SL, Lo LW, Tuan TC, Li CH, Chao TF, Chung FP, Liao JN, Chen SA. Transforming growth factor-beta1 level and outcome after catheter ablation for nonparoxysmal atrial fibrillation. *Heart rhythm : the official journal of the Heart Rhythm Society* Jan 2013;10:10-15.
403. Cabrera-Bueno F, Medina-Palomo C, Ruiz-Salas A, Flores A, Rodriguez-Losada N, Barrera A, Jimenez-Navarro M, Alzueta J. Serum levels of interleukin-2 predict the recurrence of atrial fibrillation after pulmonary vein ablation. *Cytokine* Mar 2 2015;73:74-78.
404. Park SJ, On YK, Kim JS, Choi JO, Ju ES, Jeong DS, Park PW, Jeon ES. Transforming growth factor beta1-mediated atrial fibrotic activity and the recovery of atrial mechanical contraction after surgical maze procedure. *International journal of cardiology* Apr 5 2013;164:232-237.